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 Peptide nucleic acids (PNAs) were used as encoding tags to enable the 
analysis of peptide libraries by PNA/DNA hybridisation onto DNA microarrays. This 
allowed entire peptide libraries to be organised and sorted in a two dimensional 
format whereby all library members could be interrogated and analysed on a one-by-
one basis. In this thesis, PNA-encoded peptide libraries, generated by split-and-mix 
library synthesis, were screened for a variety of functions. 
 Peptide sequences identified from the screening of a PNA-encoded library 
were analysed in detail as the first specific substrates for chymopapain. A new PNA-
encoded library consisting of D-amino acids was synthesised and screened with a 
number of proteases in attempts to identify novel/unusual substrates. 
 PNA-encoded libraries were also used in the screening of peptide libraries for 
other activities. Thus substrates for catalyst-free Hüisgen cycloaddition were 
identified following the reaction between an alkyne modified peptide library and 
azidofluorescein, while cell-penetrating peptides were identified by hybridization of 
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Chapter 1 Introduction. 
 This thesis presents the application of peptide nucleic acids (PNAs) in high-
throughput screening. It starts with an introduction to PNAs, the concept of split-and-
mix synthesis and a review of current encoding methodologies. Finally, the synthesis 
of PNA-encoded libraries that will be used throughout this thesis is also presented. 
 In chapter 3, an example of a PNA-encoded high-throughput peptide library 
screening is demonstrated. The first specific substrates for chymopapain, which were 
identified by this method, were studied and their kinetic parameters were determined. 
In addition, other two encoded libraries were screened as potential substrates for 
chymopapain exploring D-amino acid-containing peptides. It becomes interesting to 
screen for D-amino acid-containing peptides as specific substrates for proteases due 
to the possible applications that such novel sequences would have, and a high-
throughput screening method would be the most powerful approach of being able to 
detect/find them. Two encoded D-amino acid containing peptide libraries were 
therefore screened to find substrates of two proteases, chymopapain and a newly 
discovered protease – gumby. 
 In chapter 4, screening of the PNA-encoded peptide library as potential 
substrates for self-promoting Hüisgen cycloaddition is presented. The characteristics 
of the reaction are discussed. While Cu(I) is the catalyst for the reaction, the 
importance of the absence of metal catalyst, especially in biological system, is 
essential. After library screening under the catalyst-free conditions and data analysis, 
initial peptides of interest are identified. 
 2 
 Chapter 5 thesis introduces cell penetrating peptides (CPPs) and the screening 
of PNA-encoded library for novel CPPs. It starts with the delivery of known peptides 
capable of cellular delivery conjugated to PNA oligomers. The PNA-encoded peptide 
library is tested with two different cell lines (HeLa and B16F10) and the internalized 
sequences are analysed in a high-throughput manner. The “hit” peptides as cellular 
delivery agents are synthesised and their cellular delivery is evaluated and compared 
with known delivery agents. 
 3 
Chapter 2: Synthesis of PNA monomers and PNA-encoded 
peptide libraries. 
2.1 Introduction to peptide nucleic acids. 
 Peptide nucleic acids (PNAs) were first reported in 1991 by Nielsen as a 
DNA mimic in which the sugar-phosphate backbone of DNA had been replaced by a 
repeating polyamide chain of N-(2-aminoethyl)glycines (Figure 2.1)(1). PNAs can 
hybridise efficiently to complementary DNA or RNA sequences according to 
standard base paring rules. Due to the lack of charge on the PNA backbone, binding 
affinities of PNA toward DNA and RNA, under physiological conditions, are higher 
than those of DNA to DNA, due to the presence of two negatively charged phosphate 
diester backbones in the latter instance. PNAs are resistant to degradation by 
nucleases and proteases and because of their pseudo peptidic backbone, their 
physical properties are more akin to peptides than nucleic acids. 
 
Figure 2.1: Hybridisation between PNA and DNA. 
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 PNA (due to its chemical make up) can hybridise to DNA in either 
orientation, however the prefered orientation in the hybridisation of PNA to DNA is 
with amino terminus of the PNA facing the 3’-end of DNA, as shown in Figure 2.1 
(the so-called antiparallel orientation). The alternative orientation results in about a 
13°C difference in melting temperature (Tm) for a PNA/DNA duplex and 21°C for a 
PNA/RNA duplex(2). 
2.2 Applications of peptide nucleic acids. 
 2.2.1 Antisense therapy. 
 Antisense therapy is based on the treatment of genetic disorders by 
preventing translation of mRNAs into proteins. Antisense-oligonucletides (AS-NOs, 
modified oligodeoxynucleotides) often express their antisense activity in two major 
mechanisms. On the one hand, AS-NOs are designed to activate RNase, enzyme 
which cleave RNA moiety of a DNA-RNA duplex, on the other hand, they inhibit 
translation of the mRNA at ribosome by steric blockade (3). PNAs are one type of the 
AS-NOs. Since PNA-RNA hybrids are not substrates of enzyme and they have high 
binding efficiencies, their mode of action is believed to be translation-blocking rather 
than inducing RNA degradation(4,5). 
 2.2.2 Fluorescent in situ hybridisation. 
 Fluorescent in situ hybridisation (FISH) is a method by which fluorescently 
labeled probes target specific sequences in a cell. Using DNA probes, a number of 
problems can be faced, for example, degradation of probes by nucleases and non-
specific binding. 
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 PNA is one of the DNA mimics that have been used in FISH. PNA/DNA 
duplexes have higher thermal stability compared to DNA/DNA duplexes and 
therefore shorter sequences are required. In addition, the destabilising effect of a 
single-base mismatch in PNA/DNA duplexes is higher than that in DNA/DNA 
duplexes, resulting in higher specificities of detection(6). Examples of this technique 
are the detection and identification of bacteria existing in the biofilms of chronic 
wounds(7). Indeed a commercial system is now available based on PNA hybridisation 
for bacterial detection. 
 2.2.3 Nucleic acid capture. 
 PNAs have been used as tools in nucleic acid purification and recovery 
(which is often performed using DNAs). PNA probes show much more rapid and 
efficient binding/recovery of the target nucleic acids compared to DNA probes under 
low salt conditions. These probes have also been found to capture target DNAs at 
concentrations as low as zeptomolar (x10-21 M)(8), while PNA-loaded beads have 
been used to capture RNA in an automated manner with higher efficiency than DNA 
beads(9). 
2.3 Synthesis of peptide nucleic acids building blocks. 
2.3.1 Protecting groups used in peptide nucleic acid monomers synthesis. 
 The synthesis of PNA oligomers is performed by the coupling of building 
blocks, so called monomers, based on derivatives of N-(2-aminoethyl)glycine. Four 
natural nucleobases are used with three of these building blocks containing two 
amino groups (an exocyclic amine and the N-(2-aminoethyl)glycine unit) (Figure 
 6 
2.2). Orthogonal protecting groups are therefore (like for DNA synthesis) necessary 
















































Adenine monomer Cytosine monomer
Guanine monomer Thymine monomer  
Figure 2.2: PNA monomers of four nucleobases. 
 
 The combination of acid labile Boc and the less acid labile carboxybenzyl 
(Cbz) were introduced in 1994(10). Boc being removed by treatment of 50% TFA 




Figure 2.3: Adenine monomer protected with Boc (chain terminal) and Cbz (side chain). 
 7 
 Basic-labile 9-fluoren-9-ylmethoxycarbonyl (Fmoc) and Cbz was a 
combination introduced in 1995 (Figure 2.4)(11). In addition to preventing undesired 
side reactions in the oligomerization, the Cbz protecting group has also found to 

















Figure 2.4: Cytosine monomer protected with Fmoc and Cbz. 
 
 The combination of Fmoc and the acid-labile mono-methoxytrityl (Mmt) 
group was introduced in 1996 (Figure 2.5)(12). PNA monomers with these protecting 
groups can be used in automated peptide synthesizers with standard Fmoc 
deprotection chemistry to give oligomers. Final treatment with 95% TFA giving 


















Figure 2.5: Adenine monomer protected with Fmoc and Mmt. 
 
 Basic-labile Fmoc and acid-labile benzhydroloxycarbonyl (Bhoc) protected 
PNA monomers have been successfully used in solid phase synthesis (Figure 2.6). 



















Figure 2.6: Guanine monomer protected with Fmoc and Bhoc. 
 
 The Bradley group has introduced a technique where PNA could be 
synthesised using monomers orthogonal to Fmoc-amino acids(14-16). The PNA 
monomers designed are shown in Figure 2.7(17) which the amino terminus protected 
with 1-(4,4-dimethyl-2,6 dioxacyclo-hexylidene) ethyl (Dde) and the exocyclic 
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amino groups of the nucleobases protected (if necessary) with acid-labile mono-
methoxytrityl (Mmt) groups. 
 
Figure 2.7: PNA monomers for the synthesis of PNA-peptide conjugate. 
 
 The synthesis of these monomers starts with the synthesis of the Dde 
protected backbone as shown in Scheme 2.1. 
 
Scheme 2.1: Synthesis of Dde-protected backbone; Reagents and conditions: (i) 1 equiv. DCC, 0.1 
equiv. DMAP, DMF 60°C, 16 h; (ii) 16 h; (iii) 10 equiv. SOCl2, MeOH, reflux, 16 h.; (iv) 2 equiv. 
DIPEA, 1 equiv. 2.3; DCM/EtOH (1/1), 16 h. 
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 Thus Dde-OH 2.3 was prepared from 5,5-dimethyl-1,3-cyclohexanedione 2.1 
and acetic acid 2.2 in the presence of DMAP (0.1 equiv.) and DCC (1.0 equiv.) with 
gentle heat. Ethylendiamine 2.4 was alkylated with chloroacetic acid 2.5, giving 2-
aminoethylglycine 2.6 which was esterified to give ester 2.7. The N-terminus was 
protected by reacting with Dde-OH 2.3, giving methyl N-{2-[1-(4,4-dimethyl-2,6-
dioxo-cyclohexyliden)-ethylamino]-ethyl}-glycinate 2.8.  
 The nucleobases were alkylated with methyl bromoacetate and, for those with 
exocyclic amino groups, protected with the Mmt group. Thus (Scheme 2.2) thymine 
2.9 was alkylated in DMF with methyl bromoacetate using K2CO3, and the resulting 
methyl ester was then saponified with NaOH to give thymin-1-yl acetic acid 2.10. 
 
Scheme 2.2: Thymine derivatization; Reagents and conditions: (i) 1 equiv. K2CO3, DMF, N2 atm, 16 
h; (ii) 10% NaOH (aq), reflux, 10 min. 
 
 Cytosine 2.11 was initially protected by reacting with Mmt-Cl in pyridine. 
Mmt-protected cytosine 2.12 was then alkylated similarly to thymine to give [N4-(4-




Scheme 2.3: Cytosine derivatization; Reagents and conditions: (i) 1.5 equiv. Mmt-Cl, 1.0 equiv. 
NEM, Pyr, 40 ºC, overnight; (ii) 1 equiv. K2CO3, 1.0 equiv. methyl 2-bromoacetate, DMF, N2 atm., 
overnight; (iii) 10% NaOH (aq), reflux, 10 min. 
 
 The adenine derivatives were prepared in a slightly different manner to those 
of cytosine. Adenine 2.14 was firstly alkylated (2.15), prior to protection (as for 
2.12) with [N6-(4-Methoxytrityl)-adenin-9-yl]-acetic acid 2.16 obtained after 
saponification with NaOH (Scheme 2.4). 
 
 
Scheme 2.4: Adenine derivatization; Reagents and conditions: (i) 1.1 equiv. NaH, 1 equiv. methyl 2-
bromoacetate, DMF, N2, 4 h;  (ii) 1.5 equiv. Mmt-Cl, 1 equiv. NEM, DCM, 40°C, 3 h, then 25°C, 16 
h; (iii) 1 N aqueous NaOH, reflux, 2 h. 
 
 Once the Dde-protected backbone and nucleobase derivatives were available, 
these two parts were coupled using DCC and HOBt (Scheme 2.5). Yields for these 3 



























Scheme 2.5: Coupling of Dde-protected backbone and derivatized nucleobases; Reagents and 
conditions: (i) 1.2 equiv. DCC, 1.0 equiv. HOBt, 16 h. 
 
 Saponification of esters 2.17 (A, C, T) was carried out using 1 M Cs2CO3 in 
1:1 MeOH/H2O, with PNA monomers obtained in the range of 73-85% from ester 
2.17 (Table 2.1). 
 
Nucleobase % Yield (2.17) % Yield (monomer) 
Thymine 92 73 
Cytosine(Mmt) 69 80 
Adenine(Mmt) 53 85 
 
Table 2.1: Yields of coupling of Dde-protected backbone and different derivatized nucleobases (2.10, 
2.13, 2.16 to 2.17) and PNA monomers. 
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2.4 Synthesis of peptide nucleic acids-encoded peptide libraries. 
2.4.1 Split-and-mix synthesis. 
 Split-and-mix synthesis was reported by Furka as a method to synthesise 
libraries of peptide mixtures using solid phase synthesis (Scheme 2.6)(18). This 
method starts with dividing the solid support into m portions and they are reacted 
with m different building blocks (amino acids). After reaction, the portions are mixed 
into one pool and divided again into m portions (each portion contains m different 
compounds). These react with a second building block, and the process is repeated 
until the required length of the peptide is reached. While the reaction number 
increases linearly (m  2m  3m  nm), the number of products increases 















































mix, split into 3 and react with B1,B2,B3
mix, split into 3 and react with C1,C2,C3
 
Scheme 2.6: Split-and-mix synthesis. The solid support is devided into 3 portions (m = 3) and reacted 
for 3 rounds (n = 3), giving 27 (33) products from 9 (3x3) reactions. 
 
 Although this approach can produce potentially millions of peptides (each 
attached to a bead), the identity of the peptide on a bead can be difficult to determine. 
This therefore led to methods of bead encoding. 
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2.4.2 Encoding methods in combinatorial chemistry. 
 2.4.2.1 DNA encoding. 
 In 1992, Needels(19) and Brenner(20) introduced a method to identify active 
peptides from a combinatorial peptide libraries using “genetic” tags. A unique DNA 
tag for each amino acid was chemically attached to solid support in the split-and-mix 
library synthesis, resulting in each peptide being encoded by a unique DNA 
sequence. The active peptides/beads had their DNA sequences amplified by PCR 
with nucleic acid sequencing revealing the peptide sequences. In one approach(19) 
peptide sequences on the solid support (with the DNA encoded peptide library) were 
screened for binding with a fluorescently labeled antibody. After analysis using a 
fluorescence-activated cell sorting instrument, the oligomers attached to the 
fluorescent beads were amplified and analysed, revealing the peptide sequences on 
the beads. 
 
 2.4.2.2 Halophenol encoding. 
 Still developed halophenol tags (Figure 2.8) which were detected by electron 
capture gas chromatography(21). Tagging reagents were attached to the solid support 
by a diazoketone functional group being converted to a reactive acylcarbene by 
rhodium trifluoroacetate. Every building block in each step was encoded by a unique 
combination of tags and the peptides/small molecules on the beads were identified by 




Figure 2.8: General structure of halophenol tags. 
 
 2.4.2.3 Colloidal barcodes encoding. 
 Colloidal barcoding technique is a method to encode the split-and-mix library 
introduced by Trau(22). In this method, fluorescent silica particles (1 µm in diameter) 
were physically immobilised onto the solid support. Each building block in every 
round was encoded by the unique combination of fluorescent silica particles and the 
libraries were decoded using fluorescent microscopy  
 
 2.4.2.4 PNA-encoded combinatorial libraries and DNA microarrays. 
 The Bradley(23), Schultz (24) and Winssinger(25) research groups developed the 
strategy of using PNAs as tags in split-and-mix library synthesis. Using PNA/DNA 
hybridisation properties, the PNA-encoded libraries could be analysed in a high-
throughput manner using DNA microarrays with all library members analysed in one 
screen. This encoding method, in which the tag is directly attached to the peptide, 
was used throughout this thesis and it is summarized in Scheme 2.7, in which PNA 
codes were conjugated to the peptides via a lysine residue and the library attached to 
the solid support using an acid-cleavable Rink amide linker (H-Rink-PEGA, Figure 
2.9). 
 17 
split into 3, react with A1,A2,A3 and encode with a1,a2,a3
A1, a1 A2, a2 A
3, a3
B1, b1 B2, b2 B3, b3
C1, c1 C2, c2 C3, c3
split into 3, react with B1,B2,B3 and encode with b1,b2,b3















































































= Lys; A, B, C = amino acids; a, b, c = PNA tags  




Figure 2.9: Structure of Rink amide linker installed on PEGA resin, with the tri-fucntional nature of 
Lys used for library synthesis, encoding and solid-phase attachment. 
 
 For encoded split-and-mix synthesis, it was necessary that the introduction of 
tags (a, b, c in Scheme 2.7) must not interfere with the introduction of the library 
building blocks (A, B, C in Scheme 2.7) and vice versa therefore protecting groups 
on the tags and library building blocks must be orthogonal. The Bradley group has 
developed a robust protecting group cleavage strategy that is orthogonal to Fmoc and 
Boc, using the Dde protecting group. The Dde group can be deprotected by 
hydroxylamine under slightly acidic conditions (mixture of NH2OH·HCl and 
imidazole) (Scheme 2.8) whilst the Fmoc group is deprotected under basic 
conditions (Scheme 2.9). 
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Scheme 2.8: Dde deprotection using NH2OH·HCl/imidazole. 
 
 
Scheme 2.9: Fmoc deprotection using piperidine. 
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 In this thesis a 625 member library was encoded with a 3 letter code, with 
three PNA monomers, A, C and T(14). For the 1296 member libraries, a 4 letter code 
composed of A, C and T monomers was used. This code, developed by Brenner(26), 
allows all the members to be isothermal and has the advantages that only three PNA 
monomers: A, C and T, were required for library synthesis. 
2.4.3 Synthesis of a 625 member FRET-based D-amino acid-containing 
peptide library. 
 The general structure of the FRET based D-amino acid containing library is 
shown in Figure 2.10, in which L-Lys was used for the conjugation of the PNA tags 


























RHOD = Rhodamine B amide








Figure 2.10: Library L 2.1. 
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 Fmoc-L-Lys(Dde)-OH (2.19) was synthesised from Fmoc-L-Lys(H)-OH 
(2.18) and Dde-OH (2.3) with a catalytic amount of TFA in refluxing ethanol 
(Scheme 2.10)(27). 
 
Scheme 2.10: Synthesis of Fmoc-L-Lys(Dde)-OH (2.18); Reagents and conditions: (i) 1.0 equiv Dde-OH 
(2.3), 0.1 equiv. TFA, EtOH, reflux(27). 
 
 Fmoc-D-Lys(Alloc)-OH (2.21) was synthesised from Fmoc-D-Lys(Boc)-OH 
(2.20). The butyloxycarbonyl group was removed by the treatment with TFA 
followed by the treatment with commercially available allyl 1-benzotriazolyl 
carbonate in the presence of TEA (Scheme 2.11). 
 
 
Scheme 2.11: Synthesis of Fmoc-D-Lys(Alloc)-OH (2.21); Reagents and conditions: (i) 1:1 TFA:DCM, 2 
h; (ii) 1.0 equiv. allyl 1-benzotriazolyl carbonate, 2.0 equiv. TEA, 2.5 h. 
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 The library synthesis scheme is summarized in Scheme 2.12. All coupling 
steps were performed under microwave irradiation, using benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as a coupling reagent. 
H-Rink-PEGA resin (Figure 2.9) was first coupled to Fmoc-L-Lys(Dde)-OH (2.19) 
followed by Fmoc protected 6-aminohexanoic acid (Fmoc-Ahx-OH) as a spacer 
(2.23). After the removal of the Fmoc group, Fmoc-D-Lys(Alloc)-OH (2.21) was 
coupled and the resulting resin 2.24 was then ready for split-and-mix synthesis. 
 The encoded split-and-mix synthesis was performed following Scheme 2.7. 
Every position on the peptide was varied with 5 different amino acids. L-Ala was 
included as one of building blocks since it was found to be the most preferable amino 
acid cleaved by chymopapain (see section 3.1 for detail). For the first three amino 
acids (AA1 to AA3), every amino acid was encoded with unique PNA triplet 
according to Table 2.2. For amino acids at position 4 (AA4), all amino acids 
presented in Table 2.2 were used, but every one was encoded with the same PNA 
triplet code (TCC) and the library was left split in 5 portions. As a result, 125 PNA 
oligos could be used to encode the whole library of 625 members and therefore only 
125 DNA probes would be needed in the analysis. 
 A chromophoric pair was introduced into the library (2.25). After Fmoc 
deprotection, the Fmoc-Ahx-OH spacer was coupled (2.26), followed by 5(6)-
carboxyrhodamine B, (2.27). The Alloc, protecting group on the Nε of D-Lys, was 
removed by tetrakis(triphenylphosphine)palladium(0). The resulting resin was 
coupled with 5(6)-carboxyfluorescein, giving a Rhodamine B amide (RHOD) and 


















































Scheme 2.12: Synthesis of a PNA-encoded tetrapeptide library consisting of D-amino acid (L 2.1); 
Reagents and conditions: (i) 2.19; (ii) 20% piperidine / DMF, 2 x 10 min; (iii) Fmoc-Ahx-OH; (iv) 2.21; (v) 
Split-and-mix library synthesis; (vi) 5(6)-carboxyrhodamine B; (vii) 12 equiv. PhSiH3, 0.1 equiv. Pd(PPh3)4 / dry 
DCM, 2 x 15 min; (viii) 5(6)-carboxyfluorescein; (5.0 equiv. amino acids, PNA monomers or dye, 4.8 equiv. 
PyBOP, 11.0 equiv. NEM/DMF, 60°C, 20 min, microwave irradiation). 
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Table 2.2: Amino acids and their PNA triplet codes used in the split-and-mix library synthesis in 
positions AA1 to AA3. 
 
 The cleavage of the PNA encoded library, as well as the removal of the acid 
labile protecting groups on the amino acid side chain and PNA nuclebases was 
achieved in one step by the treatment of the library with a mixture of TFA, 









side chain protected peptide











F2 F1and = Fluorophores
 
Scheme 2.13: The cleavage of library L 2.1 from Rink-PEGA resin; 
Reagents and conditions: (i) TFA/TIS/DCM (90:5:5), 1h.
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 In conclusion, a PNA-encoded tetrapeptide library (L 2.1) was synthesised 
using the split-and-mix approach, with a general structure of this library shown in 
Figure 2.10. 
 The removal of the Alloc group on the Nε of D-Lys of 2.27 (Scheme 2.12) 
was often unsuccessful and problematic (perhaps best described as fickle!). 
Sometimes, after cleavage of the library from the resin, the library was found not to 
contain FAM (according to UV-Visible spectroscopy). This lack of labelling was 
clearly a major concern as it came right at the end of the synthesis (rhodamine was 
always successfully coupled). Therefore removal of Alloc group was investigated in 
detail. 
 Tetrapeptide 2.29 (RHOD-Ahx-L-Ala-D-Ala-D-Ala-D-Ala-D-Lys(Alloc)) 
was synthesised on PEGA resin and its Alloc deprotection was investigated using 
combinations of palladium sources, scavengers and reaction times (Table 2.3)(28). 
Despite the number of conditions tested, no Alloc deprotection of peptide 2.29 was 
detected. 
Palladium source Scravenger Reaction time 
Pd(PPh3)4 (0.1 equiv.) PhSiH3 (5.0 equiv.) 15 min. (x2) 
Pd(PPh3)4 (0.1 equiv.) Me2NH·BH3 (5.0 equiv.) 15 min. (x2) 
Pd(OAc)2 (0.1 equiv.) PhSiH3 (5.0 equiv.) 15 min. (x2) 
Pd(OAc)2 (0.1 equiv.) Me2NH·BH3 (5.0 equiv.) 15 min. (x2) 
Pd(PPh3)4 (1.0 equiv.) PhSiH3 (5.0 equiv.) 15 min. (x2) 
Pd(PPh3)4 (1.0 equiv.) Me2NH·BH3 (5.0 equiv.) 15 min. (x2) 
Pd(PPh3)4 (0.1 equiv.) PhSiH3 (5.0 equiv.) 30 min. (x2) 
 
Table 2.3: Reaction conditions used in attempts of Alloc deprotection(28). 
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 In conclusion, since the removal of the Alloc group was so problematic this 
protecting group could not be used reliably in the library synthesis. Another library 
(L 2.2) was designed and synthesised using a different strategy. 
2.4.4 Synthesis of a 1296 member D-amino acid-containing peptide 
library. 
 In this tetrapeptide library, each amino acid was encoded with a PNA quartet 
containing three PNA monomers (A, C and T). Each position in the tetrapeptide was 
varied with 6 different amino acids thus the library consisted of up to 1296 members 
(see Table 2.4). 
 D-amino acids used in the library synthesis contained a variety of side-chain 
properties [basic (D-Lys), acid (D-Glu), aromatic (D-Tyr), cyclic (D-Pro), small (D-
Ala) and achiral (Gly)]. 







Table 2.4: Amino acids and PNA codes used in the split-and-mix library synthesis of libraries L 2.2 
and L 2.3. 
 
 The library L 2.2 was designed such that it had FAM at the N-terminal end of 
the peptide and RHOD at the N-terminal end of the PNA tag. Although FRET might 
not be obtained from library L 2.2, cleaved sequences could be identified from the 
ratio and relative decreases of FAM intensity. Because of the large number of library 
members, the variation of hybridisation efficiency or differences in concentration 
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across the microarray might exist; therefore, decreases in FAM intensities might be 
the result of these causes besides the cleavage of peptides. RHOD at the PNA oligo 
would thus be an internal control and the ratios of FAM/RHOD would be used 
instead of absolute FAM intensities.  
 In library L 2.2, PNA tags were conjugated to a tetrapeptide via a D-Lys core. 
Therefore, orthogonally protected, Fmoc-D-Lys(Dde)-OH (2.30), was firstly 
synthesised as shown in Scheme 2.14(27). 
 
Scheme 2.14: Synthesis of Fmoc-D-Lys(Dde)-OH (2.30); Reagents and conditions: (i) 1:1 TFA:DCM, 2 h; 
(ii) 1.0 equiv. 2.3, 0.1 equiv. TFA, EtOH, reflux(27). 
 
 The synthesis of library L 2.2 is summarised in Scheme 2.15. Synthesis 
started with the coupling of Fmoc-D-Lys(Dde)-OH (2.30) onto H-Rink-PEGA resin. 
Resin 2.31 was then used for library synthesis (Table 2.4). The library (2.32) was 
modified by coupling with the Fmoc-Ahx-OH spacer onto the peptide chain (2.33), 
followed by 5(6)-carboxyfluorescein, giving the FAM labeled PNA-encoded 
tetrapeptide library (2.34). The same spacer, Fmoc-Ahx-OH, was introduced onto the 
PNA tag after removal of the Dde group, and 5(6)-carboxyrhodamine B was coupled 



































Scheme 2.15: Synthesis of a PNA-encoded tetrapeptide library containing D-amino acids as potential 
substrates for chymopapain (L 2.2); Reagents and conditions: (i) 2.30; (ii)Split-and-mix library synthesis; 
(iii) 20% piperidine / DMF, 2 x 10 min; (iv) Fmoc-Ahx-OH; (v) 5(6)-carboxyfluorescein; (vi) 
NH2OH·HCl/imidazole in NMP/DMF (5:1), 1 h.; (vii) 5(6)-carboxyrhodamine B; (5.0 equiv. amino acids, PNA 
monomers or dye, 4.8 equiv. PyBOP, 11.0 equiv. NEM/DMF, 60°C, 20 min, microwave irradiation). 
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 The dual colour-labelled library (2.36) was cleaved from the solid support 
and deprotected as in Scheme 2.13 to give library L 2.2, whose structure is shown in 
Figure 2.11, and which was obtained upon precipitation. UV/Vis analysis confirmed 















RHOD = Rhodamine B amide


















2.4.5 Synthesis of a 1296 member alkyne-modified peptide library. 
 In the screening of the peptide library as potential substrates for metal-free 
Hüisgen cycloaddition (L 2.3), an alkyne functional group needed to be available on 
the peptide. The synthesis of library L 2.3 is shown in Scheme 2.16, starting from 





























Scheme 2.16: Synthesis of PNA-encoded tetrapeptide library consisting of D-amino acid as potential 
substrates for metal-free Huisgen cycloaddition (L 2.3); Reagents and conditions: (i) 20% piperidine / 
DMF, 2 x 10 min; (ii) 5-hexynoic acid; (iii) NH2OH·HCl/imidazole in NMP/DMF (5:1), 1 h.; (iv) Fmoc-Ahx-
OH; (v) 5(6)-carboxyrhodamine B; (5.0 equiv. amino acids, PNA monomers or dye, 4.8 equiv. PyBOP, 11.0 
equiv. NEM/DMF, 60°C, 20 min, microwave irradiation). 
 
 Resin 2.32 was deprotected, followed by coupling of 5-hexynoic acid (2.37). 
The next step was modification of the PNA chain. Fmoc-Ahx-OH was coupled as a 
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spacer after removal of the Dde group (2.38). After deprotection of the Fmoc group, 
5(6)-carboxyrhodamine B was coupled, giving rhodamine B amide-labelled library 
(2.39). 
 After cleavage of 2.39 with TFA and precipitation, library L 2.3 (Figure 
2.12) was obtained as a red solid. The presence of the acetylene group was confirmed 
by both the qualitative nynhidrin test (before cleavage), which gave the expected 
negative result following coupling of 5-hexynoic acid (2.37) and infrared 
























Figure 2.12: Library L 2.3. 
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2.4.6 Synthesis of a 625 member PNA-encoded cell-penetrating peptide 
library. 
 A 625-membered library of PNA encoded cell-penetrating peptide library (L 
2.4) was synthesised. Each position of the tetrapeptide library was varied with 5 
building blocks, each of which was encoded by a unique PNA triplet. 
 Besides amino acids, N-6-aminohexyl-glycine (2.40, also known as lysine-
like peptoid monomer, Llp) was used as one of the building blocks. The building 
blocks and PNA triplets used in the synthesis of library L 2.4 are shown in Table 
2.5. 
 
Amino acid (AA1-AA2) Amino acid (AA3-AA4) PNA code (N to C) 
2.40 2.40 TAA 
Glu Glu ATA 
Pro Pro TCC 
Gly Gly CTC 
Cys Tyr AAC 
Table 2.5: Building blocks and their PNA triplet codes used in split-and-mix library synthesis of cell-
penetrating peptide library (L 2.4). 
 
 The synthesis of L 2.4 is summarised in Scheme 2.17. A PNA-encoded split-
and-mix library synthesis was performed starting from 2.22, on which L-Lys was 
used as a core of the conjugate, resulting in the library on the solid support 2.41. 
After removal of the Fmoc group, the peptide chain was capped by reacting with 
acetic anhydride (2.42). The PNA tag was coupled to the Ahx spacer after Dde 
deprotection (2.43), followed by labelling with 5(6)-carboxyfluorescein to give the 
FAM-labelled PNA-encoded tetrapeptide library 2.44. After TFA cleavage of 2.44, 





































Scheme 2.17: Synthesis of a PNA-encoded tetrapeptide library of potential cell-penetrating peptides; 
Reagents and conditions: (i) 2.19; (ii) 20% piperidine/DMF, 2 x 10 min; (iii) Fmoc-Ahx-OH; (iv)Split-and-mix 
library synthesis; (v) 1:1 (v/v) Ac2O:Py, r.t., 1.5 h.; (vi) NH2OH·HCl/imidazole in NMP/DMF (5:1), 1 h.;  
(vii) 5(6)-carboxyfluorescein; (5.0 equiv. amino acids, PNA monomers or dye, 4.8 equiv. PyBOP, 11.0 equiv. 





























Figure 2.13: Library L 2.4. 
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Chapter 3: Screening of an encoded D-amino acid 
containing peptide library – looking for new and unusual 
potential protease substrates. 
3.1 Screening of a PNA-encoded peptide library with chymopapain. 
3.1.1 Chymopapain. 
 Chymopapain is a cysteine protease, obtained from the plant Carica papaya, 
that is used for a number of biomedical applications. It is used for pain relief in the 
treatment of herniated invertebral disks (chymodiactin)(29,30), thereby reducing 
pressure on the nerve root, whereas orally administered chymopapain is used to treat 
intestine cuticles produced by neumatoids(31). It is also one of the components of 
contact lens cleaning liquids(32). 
 The catalytic mechanism of cysteine protease is summarised in Scheme 3.1. 
The cycle starts with deprotonation of a thiol in the enzyme’s active site by a basic 
side chain, usually a histidine residue (3.1). The nucleophilic attack on the peptide’s 
carbonyl carbon by the deprotonated cysteine side chain leads eventually to the 
release of the amine (3.2). The next step is the release of carboxylic acid (3.3) (via 


































































Scheme 3.1: Catalytic cycle of cysteine protease. 
 
3.1.2 Fluorescence resonance energy transfer. 
 Fluorescence resonance energy transfer is a phenomenon of energy transfer 
between two chromophores. The donor fluorophore, when excited, transfers energy 
to the acceptor chromophore, avoiding the release of this energy at its emission 
wavelength. FRET takes place if these two conditions occur: 
1. Both chromophores must be close, typically less than 10 nm. 
2. The emission spectrum of the donor chromophore must significantly overlap 
with the absorption spectrum of the acceptor chromophore. 
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 In an ideal situation, the donor chromophore is excited at λ1, emits at λ2 and 
acceptor chromophore is excited at λ2, emits at λ3, (the overall process can be 
summarized as shown in Figure 3.1). In this scenario, when the system is excited at 
λ1, emission at λ3 is observed. In another case, the acceptor chromophore does not 
emit light and is known as a dark quencher. 
 
Figure 3.1: Schematic explanation of the FRET principle. 
 
3.1.3 PNA-encoded peptide libraries. 
 PNA has been used to encode peptide libraries generated using the split-and-
mix approach. During the synthesis of the libraries, each building block was encoded 
(or tagged) with a unique PNA code. The Bradley group has developed a synthetic 
protocol for the synthesis of PNA encoded peptide libraries, using a set of Dde-
protected PNA building blocks(23). The Dde protecting group is orthogonal to the 
Fmoc, Alloc and Boc groups, enabling orthogonal library synthesis and tagging. 
PNA-encoded peptide libraries have been analysed using DNA microarrays with the 
PNA/DNA hybridisation properties, allowing each and every library member to be 
analysed by pull-down on a DNA microarray. The libraries consist of a number of 
variable positions. Each was encoded with a unique PNA triplet. After the incubation 
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with protease or tyrosine kinase (depending on the purpose of the libraries) each 
library was hybridised onto a DNA microarray containing DNA sequences 
complementary to the PNA tags of all library members (with non complementary 
DNAs as a control). 
 As an example, a 10,000-member library for profiling tyrosine kinases(16), 
was developed. Library members were nonapeptides with 4 variable positions, two 
positions on each side of the Tyr (phosphorylation site) (Figure 3.2). Each position 
was varied with ten amino acids and each amino acid encoded with PNA triplet to 
give encoding tag composed of 12 PNA monomers. The resulting 10,000-membered 
peptide library was then treated with Abelson tyrosine kinase, allowing selective 
members to be phosphorylated. 
 
Figure 3.2: Structure of a 10000-membered PNA-encoded library for profiling Tyrosine kinases. 
 
 The incubation and hybridisation of the library is shown in Scheme 3.2. The 
library was incubated with Abelson tyrosine kinase (Abl) (the tyrosine kinase that is 
involved in the regulation of cell proliferation, transcription, and apoptosis) and 
ATP, resulting in the phosphorylation of any peptide recognized by Abl. The library 
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was then pulled-down onto a DNA microarray. Each of the 10,000 peptides was 
delivered to a specific location on the microarray by the formation of antiparallel 
PNA/DNA duplexes. The arrays used contained 22,575 features with 10,000 
oligonucleotide sequences complementary to the PNA sequences (each in duplicate) 
and 2,575 control DNA sequences that were designed to be non-complementary to 
any of the PNA tags in the library. The phosphorylated peptide sequences were 
identified using a primary/secondary antibody approach. An antiphosphotyrosine 
antibody (mouse IgG) was added onto the array followed by addition of a Cy3-
labeled secondary antibody (antimouse IgG), resulting in Cy3 labelling on 
phosphorylated peptide sequences, which were detected by scanning the microarray 
using Cy3 filter. Since every library member was labelled with fluorescein, the ratio 
of Cy3/fluorescein provided an internal control for each and every member of the 
library, which was crucial due to natural variations in melting temperatures, 
concentrations, as well as differences in hybridisation efficiency between the 10,000 





Scheme 3.2: Schematic representation of the hybridisation of a PNA-encoded library incubated with 
the protein tyrosine kinase Abl and ATP onto a DNA microarray followed by identification of the 
“hits” using an antiphosphotyrosine antibody and a secondary Cy3-labeled antibody(16). 
 
 155 Peptide sequences showing the highest Cy3/fluorescein ratio were 
identified as “hits”. Analysis of these “hit” sequences (Figure 3.3) showed that the 
positions AA1 and AA4 have broad amino acid acceptance while AA2 and AA3 (the 
position next to phosphorylation site) have higher specificity of amino acids. Glu was 
the most frequent amino acid found in position AA3. In addition, Ser and Val were 
also observed at this position. For the position AA2, polar amino acid Ser and acidic 
amino acid Glu were observed as preferred amino acids. 
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Figure 3.3: Bar graphs for Abl showing the proportion of amino acids at the four randomized 
positions (AA4, AA3,AA2, and AA1) in the 155 “hits”. 
 
 The 10 peptides best recognized by Abl, showing the highest Cy3/fluorescein 
ratios, are shown in Table 3.1. By running a protein basic local alignment search tool 
(BLAST) search using the Swiss-Prot database using the top 25 sequences from the 
library, the results showed that the “hit” sequences from the library were in 
agreement with known substrates for Abl. For example, the second top sequence 
(SEYES) was the well known Abl substrate c-Jun aminoterminal kinase. These 



















Table 3.1: 10 Peptide sequences identified from the 10,000 library screen with Abl kinase. 
 




 A library of FRET-based hexapeptides consisted of four variable positions 
was synthesised using a PNA-encoded split-and-mix protocol. Each position was 
varied with 10 amino acids, giving rise to 10,000-membered library (Figure 3.4). 
Each amino acid was encoded with PNA triplet, which had been designed in such a 
way that the resulting oligomers could be hybridised only in one orientation (PNA N-
teminus facing the DNA 3’-end) by the introduction of common PNA monomers 
onto both ends of the oligomers (AAG on the N-terminus and CC on the C-terminus). 




Figure 3.4: General structure of the 10000 member PNA-encoded FRET base peptide library. 
 
 The absorption/emission spectra of chromophores used in this library are 
shown in Figure 3.5. The overlap of the fluorescein (FAM) emission wavelength and 
tetramethylrhodamine (TAMRA) absorption wavelength shows that FRET will take 
between these chromophores (red area). 
 
Figure 3.5: absorption/emission spectra of fluorescein and tetramethylrhodamine. 
 
 This library was used in the determination of the substrate specificity of 
chymopapain using a DNA microarray consisting of DNA oligomers complimentary 
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to all PNA oligos existing in the library (in duplicate). Upon hybridisation, the PNA 
tags brought each library member to specific position on the DNA microarray having 
a complementary DNA sequence. Since the DNA sequences of every position on the 
microarray are known, the peptide sequence of the library member hybridised onto 
each position could be identified due to the amino acid-PNA tag correspondence. 
 The library, before treatment with chymopapain, was first hybridised onto a 
DNA microarray and scanned using TAMRA and FAM filter sets. Analysis of the 
resulting images showed no signal on the control spots, indicating that no unselective 
binding occurred in the hybridisation process while the presence of fluorescent 
intensities confirmed the success of library synthesis. 
 After treatment with chymopapain, the library was hybridised onto a DNA 
microarray and the array was scanned similarly to that of untreated library. The ratios 
of the FAM/TAMRA intensities were analysed and for the “hit” sequences, the 
FAM/TAMRA ratios would be expected to be significantly increased due to the 
cleavage of TAMRA from the peptide (Figure 3.6). 
 
Figure 3.6: Comparison of cleaved and non-cleaved peptide sequences. 
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3.1.5 Analysis and identification of possible “hit” peptide sequences 
derived from the screening of the 10,000-member PNA-encoded peptide 
library. 
 The 10,000-membered PNA encoded peptide library contains FRET pair 
FAM and TAMRA. Besides being a FRET acceptor, TAMRA also acted as an 
internal control. The internal control was necessary in the library screen since the 
factors that affect fluorescent intensities exist, including a broad range of melting 
temperature, variation in hybridisation efficiency and difference in concentrations of 
library members across the array. The fluorescent ratios were used instead of 
absolute fluorescent intensities in order to minimize these effects. Therefore the 
cleaved peptide sequences were identified by the high ratios of FAM (of treated 
library) to TAMRA (of control library). 
 Unmodified library was first hybridised on the DNA microarray as a control. 
The customized microarray contained 22,575 spots (10000 DNA sequences 
complementary to PNA tags in duplicate plus 2,575 non-complementary sequences). 
Microarray scanning (using both TAMRA and FAM filter sets) revealed that the 
fluorescent signals could be detected only on spots complementary to PNA tags and 




Figure 3.7: A 10 000 member uncleaved PNA-encoded library hybridised onto a 22575 custom DNA 
microarray. Empty circles represent spots containing DNA oligomers that were not complementary to 
any PNA oligomer in the library. 
 
 Following enzymatic treatment, the library was hybridised onto the DNA 
microarray and scanned. The FAM/TAMRA ratios were obtained and accepted if the 
standard deviation of the duplicates were less than 0.25, resulting in 8,685 acceptable 
data points (Figure 3.8). From the 8,685 peptide sequences the 100 sequences 
























































































































Figure 3.8: Peptide sequences whose FAM/TAMRA ratios have standard deviation of the duplicate 
less than 0.25. 
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APVV AFNK AKKY FLLL AVPA 
AFSV AFVV AVSL AFDF AVNL 
AVFK AFVY YFLS AVYK PFKV 
APPV APYV APAF AKFP APVP 
AFKF APAV AVNS APNV AFVS 
AVLY APVK PFLK AVSF AVFL 
ALLY APVL APVN FLLV AFVL 
AVFS AFSL PFVS AFKD AVLF 
AVAF AVAV APKF APLF AVYF 
APKV AVKS ADKV ADLY AFVK 
APVS AVFY AVDK APAS AVVK 
AVKF AFDK APFV PVVL AFKS 
APVA ALLL AFKY ALLS AFYS 
AVVF AVFV AYPV AVFN AYKF 
AVPK APVY AFFK AYKV PPVK 
AFPV AFSF ADKK ALLV FPVV 
AVAL APFK AVNF AVYS APAA 
AVKY DFKS AYVK APVD AFYK 
APAL APAK AVYV AFLK AKLL 
AVAK AVVY AVYL AYYK AYKD 
 
Table 3.2: The 100 peptide sequences (N - C) showing highest FAM/TAMRA ratios. 
 
 The preference amino acids in each position were identified using the data in 
Table 3.2 (Figure 3.9). Chymopapain showed the highest specificity for Ala at 
position AA4, Phe/Pro/Val at position AA3 and Phe/Lys/Ser/Val at position AA1 
while there was little preference for any amino acid at position AA2. In conclusion, 
the “hit” sequences from the screening of PNA-encoded library as substrates for 
chymopapain were Ala-(Phe/Pro/Val)-Xxx-(Phe/Lys/Ser/Val), where Xxx represents 
any amino acid. 
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Figure 3.9: Representation of the top 100 peptide cleaved by chymopapain from the 10000-membered 
library. 
 




 Two peptides sequences were designed and synthesised based on the 
generated “hit” sequences and evaluated as potential chymopapain substrates. These 
sequences were the hexapeptide Ser-Ala-Pro-Val-Lys-Ala and the tetrapeptide Ala-
Pro-Val-Lys. A FRET-pair was used in order to follow the cleavage of substrates 
(fluorescein (a donor chromophore) and methyl red (a dark quencher)). Fluorescein 
and methyl red were coupled to the peptides via the Lys side chain and a γ-


































































Figure 3.10: The FRET peptides used in the enzymatic evaluation of chymopapain;  
Peptide 3.4: (Methyl Red-Abu-Ser-Ala-Pro-Val-Lys-Ala-Lys(Fluorescein)-NH2); 
Peptide 3.5: (Methyl Red-Abu-Ala-Pro-Val-Lys-Lys(Fluorescein)-NH2). 
 
 The cleavage of peptides 3.4 and 3.5 was followed using a fluorescence plate 
reader equipped with 480/20 nm excitation and 520/20 nm emission filters. The 
experiments were carried out at pH 6.2 and pH 7.4 since chymopapain has a broad 
working pH range. Enzyme concentrations were determined using λmax = 280 nm and 
a mass extinction coefficient (E1%) = 18.7(34). 
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 Stock solutions (10 mM) of both FRET peptides were prepared in 
dimethylsulfoxide (DMSO). Before assay, the peptides were diluted into assay 
buffers (assay buffer 1 - 0.1 M phosphate-buffered saline [PBS], pH 7.4; assay buffer 
2 - 10 mM sodium acetate, 0.1 mM ethylenediaminetetraacetic acid [EDTA], and 1 
mM cysteine, pH 6.2) at a range of concentrations, keeping the DMSO level below 
3.5%. Chymopapain (0.3 µM in 10 mM sodium acetate, 0.1 mM EDTA, and 1 mM 
cysteine, pH 6.2) was added to the reaction mixture to a final concentration of 30 
nM. Enzymatic reactions were carried out at 37°C, and the initial rates were 
calculated using the Biotek Gen5 data analysis software (only the hydrolysis of 
peptide 3.5 is demonstrated below). The fluorescence profiles following the 
hydrolysis of peptide 3.5 (at different concentrations of substrate) by chymopapain 




Figure 3.11: Fluorescence profiles (relative fluorescence units [RFU] vs. time [s]) following the 
hydrolysis of peptide 3.5, at different concentration of substrate (µM). 
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 From the initial rates obtained from Figure 3.11, the initial rates versus 
substrate concentrations is shown in Figure 3.12 and this data was used to calculate 
Km and Vmax using the software GraFit. 
 
Figure 3.12: Initial rate versus substrate concentration from the cleavage of peptide 3.5. 
 
 The cleavage of peptides 3.4 and 3.5 were analysed by analytical HPLC. 
Figure 3.13 shows the two HPLC traces (recorded at 440 nm) of peptide 3.5 before 
(trace a) and after (trace b) enzymatic incubation, showing complete hydrolysis after 





Figure 3.13: HPLC traces recorded at 440 nm of peptide 3.5 before (a) and after (b) treatment with  
30 nM chymopapain at pH 7.4 and 37°C. 
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 Kinetic parameters for each peptide are summarized in Table 3.3. Both 
substrates showed Km values in the low micromolar range. Hydrolysis at different pH 
showed that pH did not influence Km. For both substrates, kcat at pH 7.4 was twice as 
fast as at pH 6.2. The Km of peptide 3.4 was comparable to that of the commercially 
available substrates such as benzyloxycarbonyl-lysine phenyl ester (Z-Lys-ONp) (Km 
values 7.5-10 µM for chymopapain)(35), but with improved kcat, while specificity 
would be expected to be superior. 
 
Substrate pH Km (µM) kcat (s
-1) kcat/Km (mM
-1s-1) 
Peptide 3.4 6.2 23 ±7 133 ±1.2 5797 
Peptide 3.4 7.4 26 ±10 360 ±0.3 13,845 
Peptide 3.5 6.2 50.6 ±12 246 ±0.5 4874 
Peptide 3.5 7.4 50.2 ±18 590 ±1.7 11,767 
Table 3.3: Kinetic values of the FRET peptides with chymopapain 
 
 Papain was also analysed with the same peptides and its results are shown in 
Table 3.4. The results showed that, with increasing pH, papain’s affinity for both 
substrates decreased while the turnover number increased dramatically. 
 
Substrate pH Km (µM) kcat (s
-1) kcat/Km (mM
-1s-1) 
Peptide 3.4 6.2 27 ± 10 243 ± 22 9000 
Peptide 3.4 7.4 101.5 ± 30 1503 ± 5 14,811 
Peptide 3.5 6.2 119 ± 5 475 ± 10 3992 
Peptide 3.5 7.4 200 ± 18 1773 ± 3 6250 
Table 3.4: Kinetic values of the FRET peptides with papain. 
 
 53 
 By comparing the results obtained from chymopapain and papain, it could be 
summarised as follows: 
1. For chymopapain, changing pH between pH 6.2 and pH 7.4 does not 
affect its affinity against peptide 3.4 and peptide 3.5. However, papain 
showed decreased affinity against both peptides with increasing pH. 
2. Papain has a higher turnover number than chymopapain for both 
substrates and both pH’s. 
3. Although chymopapain and papain have a broad working pH, kcat/Km 
value suggested that both enzymes have higher efficiency at pH 7.4. 
 The scissile bond of substrates was identified by analysing the chymopapain 
digested samples using liquid chromatography-mass spectrometry. Peptide 3.4 was 
cleaved at the Lys-Ala bond and peptide 3.5 was cleaved at the Lys-Lys site. 
 This result showed that lysine was preferable at position P1 but there was not 
high specificity for residues in position P1’. However, the effect of residues in 
positions P2 – P4 could not be concluded since both peptides had identical residues in 
these positions (Figure 3.10). Another peptide having the sequence of Methyl Red-
Abu-Ser-Ala-Phe-Lys-Tyr-Ala-Lys(FAM)-NH2 (peptide 3.6, Figure 3.14) was 
synthesised and incubated with chymopapain. Peptide 3.6 was found not to be 
cleaved, suggesting that Val, Pro and Ala at the position P2 – P4 are important for the 
target peptides, therefore, the optimal substrate specificity for chymopapain at P4 to 








































Figure 3.14: Peptide 3.6 (Methyl Red-Abu-Ser-Ala-Phe-Lys-Tyr-Ala-Lys(Fluorescein)-NH2). 
 
 In conclusion, two peptide substrates for chymopapain have been presented 
for the first time. These peptides showed micromolar affinity toward chymopapain 
and good turnover numbers, making them perfect candidates for chymopapain 
studies. In addition, these results also confirmed the success of high-throughput 
screening of PNA-encoded peptide libraries for the discovery of new substrates for 
proteases. 
3.2 D-amino acid-containing peptides and origins. 
 In most living organisms, only L-amino acids have been selected as building 
blocks for peptides and proteins(36), with the D-enantiomer excluded. However, D-
amino acids have been found in small amounts in some vertebrates and are widely 
found in micro-organisms especially in cell wall components. 
3.2.1 From bacteria. 
 The largest source of D-amino acids in nature may be as building blocks of 
the peptidoglycan bacterial cell wall. Peptidoglycan is a natural polymer presents in 
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both gram positive and gram negative bacteria. It consists of N-acetylmuramic acid 
(MurNAc) and N-acetylglucosamine (GlcNAc) sugar residues (Figure 3.15)(37), with 
the MurNAc attached to a pentapeptide which is cross-linked to adjacent peptide 
strands thereby strengthening the structure. The pentapeptide composition may vary 






























Figure 3.15: Peptidoglycan structure with insert showing structure of meso-DAP. 
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 Since peptidoglycan plays a major role in bacteria cell wall integrity, its 
defect results in cell lysis because of the continuing process of osmosis and the 
resulting osmotic pressure within the cell causing rupture. As a result, peptidoglycan 
biosynthesis is a key target for naturally occurring antibiotics. Examples of which are 
the β-lactam antibiotics, which inhibit cross-linking of the pentapeptides. 
3.2.2 Found in humans. 
 In various human tissues, D-aspartic acid has been detected. In tissues such as 
teeth(39,40), brain(41-43), and eye lenses(44,45) from the elderly. This presence is believed 
to be the result of accumulation over time of epimerised L-aspartic acid. There is also 
a relationship between the presence of this D-amino acid and disease. Thus Roher(43) 
reported that D-seryl and D-aspartyl residues were found in high levels in brain 
tissue from people who had died of Alzhiemers disease. Fujii(46) discovered an 
increase in the D-aspartyl residue at specific positions in a protein which is a 
component of the eye lens in older humans, with the D-asparatyl level related to 
levels of cataract disease. 
 In addition to being part of some peptides, D-amino acids are also found in 
free-acid form in mammalian tissues. D-aspartic acid has been found in rat brain, the 
retina’s of chicken’s, rat’s and human’s in the early development period although 
they quickly decrease to the same amount as in adult tissue by the time of birth(36). 
Free D-serine is also detected in many areas of the human brain, with the D-serine 




3.2.3 Other sources. 
 Dermorphine is an opioid heptapeptide with the sequence Tyr-D-Ala-Phe-
Gly-Tyr-Pro-Ser-NH2 that was first extracted from the skin of Phyllomedusa 
sauvagei, a species of frog from South and Middle America(36,48). Dermorphine is 
about one thousand times more potent than morphine in terms of activity. D-alanine 
present in this peptide is crucial for its activity. 
 Bombinins H are a group of peptides which are variants of bombinin, a 
peptide from the skin secretion of certain frogs(49). Bombinin H4 has the sequence 
Ile-D-aile-Gly-Pro-Val-Leu-Gly-Leu-Val-Gly-Ser-Ala-Leu-Gly-Gly-Leu-Leu-Lys-
Lys-Ile-NH2
(50) (Since isoleucine has two chiral centers, inversion of that at α-carbon 
atom results in D-alloisoleucine, represented as D-aile)(51). 
 Two D-amino acid-containing neuropeptides have been isolated from the 
African giant snail Achatina fulica(36). Achatin I, Gly-D-Phe-Ala-Asp, was isolated 
from its ganglia and atrium. Achatin I enhance activities of the snail’s heart in two 
ways; first, this peptide increases impulse frequency and produces spike broadening 
of a heart excitatory neuron. In another way, this neuropeptide increases the 
amplitude and frequency of the heart beat. Achatin II (the corresponding peptide with 
an L-Phe) was also found but shows no biological activity. Another peptide is 
fullicin, Phe-D-Asn-Glu-Phe-Val-NH2, which was also isolated from ganglia of the 
same snail and found to be a potent stimulator of the contraction of the penis 






3.2.4 Origins of D-amino acid-containing peptides. 
 D-amino acids can be synthesised by different mechanisms, depending on the 
organism where the D-amino acids are found. 
 
 Biosynthesis of peptidoglycan. 
 Alanine racemases are a group of pyridoxal 5’-phosphate (PLP)-containing 
enzymes, which use a pyridoxal cofactor to generate and stabilise an α-carbanion 










































PLP = pyridoxal 5'-phosphate
P = phosphate
 
Scheme 3.3: Racemization of alanine by alanine racemase 
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 Other enzymes involved in peptidoglycan biosynthesis are diaminopimelate 
epimerase and glutamate racemase. Diaminopimelate transforms LL- 
diaminopimelate (LL-DAP) to meso-diaminopimelate (DL-DAP) (see Figure 3.15 
for DAP) while glutamate racemase generates D-Glu(53). 
 
 Products of other racemases. 
 Besides alanine, racemases of other amino acids have been found. One of the 
most well studied is serine racemase, probably because D-serine is found in the brain 
of many vertebrates. Wolosker(54) purified serine racemase and studied its 
mechanism. Analysis showed that D-serine increased in direct proportion to L-serine 
decreasing, showing that L-serine was directly converted to D-serine by this enzyme, 
without a free intermediate (e.g. α−keto acid). 
 
 Chiral environment-inducing inversion of configuration. 
 α-Crystallin is a protein found mostly in eye lens, consisting of αΑ-crystallin 
and αΒ-crystallin subunits(55).  αΑ-crystallin is a peptide containing 173 amino acids. 
A D-amino acid is found in position 151 (Asp-151). In order to understand the 
stereo-inversion at Asp-151, the racemisation of Asp in a 12-amino acid peptide 
model corresponding to  αΑ-crystallin (IQTGLDATHAER) was studied. The ratio 
of D-isomer to L-isomer (D/L ratio) of the Asp in a model peptide did not exceed 1.0 
while in native protein, the D/L ratio at this position was found to be 5.7. This 
suggested that a chiral enviroment exists in the native higher order structure of 
human αΑ-crystallin which induces the inversion of L-Asp to D-Asp residues. 
 The proposed mechanism for inversion of configuration of Asp-151 is shown 
in Scheme 3.4.(55, 36) L-succinimidyl (3.7) can be converted into D-succinimidyl (3.8) 
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via achiral intermediate (3.9) by deprotonation and reprotonation. From either 
succinimidyl (3.7 and 3.8), hydrolysis can occur at either carbonyl group, resulting in 










































L- aspartyl D- aspartyl D- aspartyl
Intermediate (3.9)
 
Scheme 3.4: Formation of D-aspartyl unit in α-crystallin. 
 
 The key species in the predominance of the D-isomer of Asp-151 is 
intermediate 3.9. The native higher order structure of the protein blocked the Re-face 
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Scheme 3.5: Explanation of unequal protonation leading to predomination of D-succinimidyl in α-
crystallin. 
 
3.3 Enzymes acting on D-amino acids and their applications. 
 Because of the chiral specificity of enzymes, most L-amino acid-containing 
peptides are inert to D-amino specific enzymes, and vice versa, very few enzymes 






 D-aminoacylases are a group of enzymes that specifically deacetylate N-
acetyl-D-amino acids while they are not active against the corresponding L-amino 
acid derivatives(56) These enzymes are useful in the resolution of racemic N-acetyl 
amino acid. 
 D-aminopeptidases. 
 Aminopeptidases are enzymes which catalyze the stepwise cleavage of a 
single amino acid from the amino terminus of a peptide. Aminopeptidases acting on 
D-amino acid-containing peptides have been found in bacteria. D-aminopeptidases 
release a D-amino acid residue from the amino terminus of the peptide regardless of 
the stereochemistry of the second amino terminal amino acid(38). 
 D-aminopeptidases can be used in the synthesis of D-amino acids or D-amino 
acid containing peptides from racemic amides or esters. D-aminopeptidases can 
selectively form an acyl-enzyme complex with the D-enantiomer. Hydrolysis of this 
complex leads to enantiomerically pure amino acid. Alternatively, if this acyl-
enzyme complex is reacted with a peptide, an N-terminal D-amino acid-containing 
peptide is formed (Scheme 3.6)(38) D-alaninamide amidase is an example of an 
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Scheme 3.6: Production of D-amino acids and D-amino acid containing peptides by D-
aminopeptidase. 
 
 D-aminopeptidases have been applied in drug delivery. One strategy to 
deliver anticancer drugs to desired locations, and nowhere else, is to use an inactive 
prodrug that will be activated by enzymes located on targeted positions. 
Methotrexate (MTX) (Figure 3.16 A) is a drug widely used in chemotherapy. 
Different 2-α-aminoacyl derivatives of this molecule have been prepared and their 
suitability as prodrugs evaluated. D-Ala-MTX (Figure 3.16 B) was stable in serum 
but activated by D-aminopeptidase. This prodrug would thus be useful for 
application in antibody-directed enzyme prodrug therapy (ADEPT), where D-




Figure 3.16: (A) Methotrexate; (B) 2-D-Ala- Methotrexate. 
 
3.4 Result and Discussion. 
3.4.1 DNA microarrays. 
 Microarrays used in this thesis were either prepared by printing amino 
modified DNA sequences onto CodeLink™ slides (for library L 2.1, Figure 2.10), or 
custom designed DNA microarrays (Agilent, for library L 2.2 – L 2.4, Figure 2.11-
2.13). This section will describe only the DNA microarray prepared on CodeLink™ 
slides. 
 3’-Amino modified DNA oligos (18 bases long) with 12 bases 
complimentary to the PNA encoding oligos (6 bases were used as a spacer) were 
used for microarray fabrication. From the encoding strategy presented in 2.4.2 
(Table 2.2), library L 2.1 had 125 different PNA sequences therefore 125 
complementary DNA sequences were used for decoding. The success of the printing 
process was monitored by printing of a 3’-amino modified FAM labelled DNA 
sequence (so called printing reference). Each DNA sequence was printed with up to 
7 replicates per slide, except the printing reference which was printed 21 times. As 
the result, each slide contained 896 spots [(7x125)+21]. 
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 The microarray fabrication was performed using a Robot Microarrayer 
(Genetix QMini, UK). The process is summarised in Scheme 3.7. The surface of a 
CodeLink™ slide was modified by printing on a 3-D polyacrylamide gel matrix, 
containing N-hydroxysuccinimide (NHS) active esters. 3’-Amino modified DNA 
oligos were immobilized on this slide upon printing, with unreacted NHS active 
esters being blocked by reacting with ethanolamine. 
 
Scheme 3.7: Immobilization of DNA oligos onto CodeLink™ slides. 
 
3.4.2 PNA-encoded D-amino acid-containing peptide libraries as potential 
substrates for chymopapain. 
 PNA encoded D-amino acid-containing peptides libraries (L 2.1 and L 2.2, 
Chapter 2) were generated and treated with chymopapain in order to identify possible 
D-amino acid containing peptides as substrates of this enzyme. 
 
3.4.2.1 Screening of library L 2.1. 
 The analysis of library L 2.1 is summarised in Scheme 3.8. After incubation 
of the “D” library with chymopapain, cleaved members would have rhodamine B 
removed. As a result, the FRET would be interrupted and therefore an increase in 
FAM (FRET donor) intensity would result. As explained earlier, FAM intensity must 
be considered in comparison with the control, which was rhodamine B in this case. 
Therefore, the sequences with higher ratios of FAM (treated library) to rhodamine B 
(control library) were of interest. 
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Scheme 3.8: Screening of a FRET D-amino acid containing peptide library (L 2.1). 
 
 One portion of library L 2.1 (where AA4 was L-Ala) was screened as a 
potential substrate for chymopapain. From the 125 library members, the 12 
sequences with the highest FAM/RHOD ratios were identified (Figure 3.17) (n = 2). 
Figure 3.17: Cleaved peptide sequences from L 2.1. 
 
 From Figure 3.17, it can be concluded that, of the 125 members screened, 
three sequences, namely L-Ala-D-Ala-D-Ala-D-Ala, L-Ala-D-Ala-Gly-Gly and L-
Ala-D-Ala-D-Ala-Gly, showed significant increases in the FAM/RHOD ratio. These 
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sequences were considered positive “hits” and one of these sequences was selected 
for further study. 
 The FRET peptide from the “hit” peptides, Methyl Red-Ahx-L-Ala-D-Ala-D-
Ala-D-Ala-D-Lys(FAM)-NH2 (peptide 3.10), was synthesised. The FRET-pair were 
identical to those described in section 3.1.6. In peptide 3.10, fluorescein was 




Figure 3.18: Peptide 3.10 (Methyl Red-Ahx-L-Ala-D-Ala-D-Ala- D-Ala-D-Lys(Fluorescein)-NH2), a 
FRET peptide used in the enzymatic evaluation of chymopapain against D-amino acid containing 
peptide. 
 
 Peptide 3.10 was subjected to enzymatic digestion with chymopapain at 37°C 
and pH 7.4 and the cleavage of the peptide was followed as in section 3.1.6. The 
fluorescence profile of the hydrolysis is shown in Figure 3.19. No increase in 
fluorescent intensity was detected. The fluorescence profiles suggested that peptide 




Figure 3.19: Fluorescence profiles (relative fluorescence units [RFU] vs. time [min]) following the 
hydrolysis of peptide 3.10 by chymopapain at pH 7.4. 
 
 In order to confirm this result, peptide 3.10 (100 µM) was incubated with 
chymopapain (10 µM) at 37°C and pH 7.4 and the cleavage of peptide 3.10 was 
followed by analytical HPLC analysis at 515 nm at different reaction times (0 h, 1.5h 
and 18 h) (Figure 3.20). The HPLC analysis showed only the peak of the starting 
material, confirming that peptide 3.10 was not digested by chymopapain. 
 
Figure 3.20: HPLC traces recorded at 515 nm of peptide 3.10 following treatment with 5 µM 
chymopapain at 37°C and pH 7.4 at different reaction time. 
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 Thus although the tetrapeptide L-Ala-D-Ala-D-Ala-D-Ala showed the highest 
FAM/RHOD ratio (Figure 3.17), the cleavage of this peptide could not be detected 
when it was used as a single substrate. The possible explanation for this result is that, 
because methyl red was used as a dark quencher in peptide 3.10 while rhodamine B 
was used in the library, it is possible that methyl red could be influencing the 
cleavage of the peptide. Therefore the cleavage of “hit” sequence (peptide 3.10) 
could not be observed. 
 
3.4.2.2 Screening of library L 2.2. 
 Library L 2.2 was a 1296 membered PNA-encoded tetrapeptide library which 
contained FAM on the amino terminus of the peptide and rhodamine B amide on the 
amino terminus of the PNA chain. Therefore cleaved sequences of L 2.2 members 
would result in removal of FAM. The “hit” sequences were then identified by a 
decrease in the ratio of FAM to control chromophore (rhodamine B) (Scheme 3.9). 
 
 
Scheme 3.9: Screening of a D-amino acid containing peptide library (L 2.2) as chymopapain 
substrate. 
 
 Figure 3.21 (a) shows the FAM/RHOD ratio from library L 2.2 before 
(“control”) and after treatment with chymopapain. Both experiments did not show 
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any difference in FAM/RHOD ratios. As presented in Figure 3.21 (b), the difference 
of FAM/RHOD ratios of the control library and FAM/RHOD ratios of chymopapain 
treated library were mostly less than 0.1. In addition, as presented in Figure 3.21 (a), 
peptides containing D-Pro-D-Lys at positions AA4-AA3 or AA3-AA2 (shown in the 
boxes) had a low FAM/RHOD ratio compared to the rest of the libraries (presumably 




Figure 3.21: (a) FAM/RHOD ratio from library L 2.2 before (blue) and after treatment with 
chymopapain (pink) (b) The difference of FAM/RHOD ratios of control library and FAM/RHOD 
ratios of chymopapain treated library. 
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 These data are also presented in another format, in which the FAM intensities 
obtained from the library after the treatment with chymopapain are plotted against 
FAM intensities obtained from the library before the treatment with chymopapain (so 
called “control”) (Figure 3.22). A group of sequences showed higher FAM 
intensities following chymopapain treatment, opposite to that expected from the 
cleaved sequences (presented in the box in Figure 3.22). Members of this group 
contained D-Pro-D-Lys at positions AA4-AA3 or AA3-AA2. However, when the 
FAM/RHOD ratios were used instead of FAM intensities, the data plotted in 
diagonal lines were obtained meaning that the treatment with chymopapain did not 
change the FAM/RHOD ratios of the library members (Figure 3.23). This result 
underlines the importance of an internal control (rhodamine B in this case) in a 
library containing large number of members. 
 
 
Figure 3.22: Fluorescein intensities obtained from library L 2.2, comparing chymopapain treated 




Figure 3.23: FAM/RHOD ratios obtained from library L 2.2, after treatment with chymopapain (y-
axis) against control library (x-axis). 
 
 FRET intensities from library L 2.2, treated with chymopapain, are shown in 
Figure 3.24. FRET intensities were obtained from excitation of the microarrays at 
488 nm (FAM excitation wavelength) and the emission intensities measured at 575 
nm (RHOD emission wavelength). If FRET takes place in library L 2.2, the cleaved 
peptide would remove the donor chromophore FAM, hence a decrease in emission 
intensity because of FRET would be expected. From Figure 3.24 (a), the result 
showed that no decrease in FRET intensity was observed when the library was 
treated with chymopapain. Figure 3.24 (b) also showed that, while FRET intensities 
from most of the library members did not change, some members had FRET 
intensities that increased after the treatment with chymopapain. 
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Figure 3.24: (a) FRET intensity obtained from library L 2.2 before (blue) and after (pink) treatment 
with chymopapain (b) The difference of FRET intensities obtained from L 2.2. 
 
 It was found that many library members containing D-Pro-D-Lys at the 
positions AA4-AA3 or AA3-AA2 responded differently to the treatment with 
chymopapain compared to the rest of the library. However, the responses from those 
peptides were apparently not due to the cleavage by the enzyme because the 
intensities corresponding to both chromophores were always found to be increased 
after the treatment of the enzyme. The reason for this behaviour is unclear. One 
possible explanation is the 3-dimensional arrangement of the peptide sequences. 
Having D-Pro as one of amino acids on the specific locations of those sequences, the 
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sequences possibly folded back in a beta-turn stabilized structure, therefore they had 
a different 3-dimensional arrangement compared to the rest of the library and 
responded differently to microarray scanning. 
 Since peptide sequences containing D-Pro-D-Lys at positions AA4-AA3 or 
AA3-AA2 behaved differently compared to the rest of the library, this sequence was 
selected for further studies. A FRET tetrapeptide FAM-Ahx-D-Ala-D-Pro-D-Lys-




Figure 3.25:Peptide 3.11, (Fluorescein-Ahx- D-Ala-D-Pro-D-Lys-Gly-D-Lys(Methyl Red)-NH2), a 
FRET peptides used in enzymatic evaluation of chymopapain. 
 
 Peptide 3.11 (100 µM) was subjected to enzymatic digestion with 5 µM 
chymopapain at 37°C and pH 7.4. After 24 h the reaction (and a control, in which 
100 µM of Peptide 3.11 was incubated at 37°C and pH 7.4 without chymopapain) 
were analysed by analytical HPLC (Figure 3.26) and showed that peptide 3.11 was 





Figure 3.26: HPLC traces recorded at 515 nm of peptide 3.11 following treatment with 5 µM 
chymopapain at 37°C and pH 7.4 for 24 h. (red) and control (blue). 
 
 The result that peptide 3.11 was not digested by chymopapain thus discarded 
the possibility that dipeptide D-Pro-D-Lys is the target of chymopapain. Therefore 
no D-amino acid-containing peptide from library L 2.2 could be identified as 
substrates of chymopapain. 
 
3.4.3 PNA-encoded D-amino acid-containing peptide libraries as potential 
substrates for Gumby. 
 Gumby is a novel papain-like cysteine protease discovered by Dr. Sabine 
Cordes’s research group. Substrate for this protease is still unknown therefore the 
protocol previously presented could be used for the discovery of specific substrate(s) 
for this protease. 
 Library L 2.2 was screened as potential substrate for wild-type and mutant 
gumby. After being denatured by heating at 90°C for 20 min, library L 2.2 (600 
pmol/experiment) was treated with wild-type and mutant Gumby (11.4 pmol). The 
enzymatic reaction was allowed to proceed for 22 hours at 37°C. The reaction 
mixture was then hybridised onto DNA microarray and analysed in a similar fashion 
to that described in section 3.4.2. 
 76 
 According to Scheme 3.9, if proteolytic activity took place, the FAM/RHOD 
ratio should decrease compared to the control. This ratio, from library L 2.2 treated 
with wild-type Gumby, showed that none of the library members had different ratios 
from the majority of the library (Figure 3.27) (similar to the control). 
 Mutant Gumby showed the same result to that of wild-type. FAM/RHOD 
ratios of all library members are similar to that of control (data not shown). Therefore 
it can be concluded that none of the PNA-encoded library L 2.2 was cleaved by wild-
type or mutant Gumby. 
 




 The success of the PNA encoding strategy in the combinatorial libraries was 
demonstrated. With this strategy, specific substrates for chymopapain could be 
identified from a 10,000-membered FRET based hexapeptide library. The affinity 
and turnover number showed that these peptides are an ideal substrate for 
chymopapain. The same strategy was also used for libraries of D-amino acid-
containing peptide for the discovery of new substrate(s) for a number of enzymes. D-
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alanine might be the preferable amino acid of chymopapain, however, the digestion 
of a peptide containing D-alanine by chymopapain was not successfully 
demonstrated from any of the libraries evaluated.. 
 A non-FRET PNA-encoded library of D-amino acid containing peptide was 
screened for substrates of chymopapain and a novel protease Gumby. However, no 
library member was found to be a potential substrate for any protease used.  
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Chapter 4: High-throughput screening of an encoded 
library of peptides as potential substrates for “self-
promoting” Hüisgen 1,3-dipolar cycloadditions. 
4.1 Introduction. 
4.1.1 Hüisgen 1,3–dipolar cycloadditions. 
 In 2001, the term “Click Chemistry” was introduced by Sharpless(59). It refers 
to a series of organic reactions that display certain criteria; fast, stereospecific, 
reactions that take place under mild reaction conditions, giving product(s) in high 
yield with inoffensive by-products and with product isolation by simple 
nonchromatographic methods. “Click reactions” include many classes of 
transformation; cycloaddition, nuclephilic substitution, carbonyl chemistry of the 
“non-aldol” type and additions to carbon-carbon multiple bonds. 
 
Carbon-carbon unsaturated bonds 
 Carbon-carbon unsaturated bonds are relatively more reactive than carbon-
carbon single bonds making olefins and carbon-carbon triple bonds attractive starting 
materials to the synthetic chemist. Because of their reactivities, compounds 
containing carbon-carbon unsaturated bonds are good reagents for “Click” 
transformations. 
 Among the number of reactions considered, the Hüisgen 1,3–dipolar 
cycloaddition is one of the most well known due to its extensive applications in 
various fields such as chemistry, biology and materials science. This cycloaddition 
involves 1,3-dipolar compounds and diatomic dipolarphiles, giving rise to 5-
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membered heterocycles. 1,3-Dipolar molecules can be compounds such as azides, 
nitrile oxides, and ozone, while alkynes and nitriles are examples of dipolarphiles. 
One of the most studied couples may be the azido and alkyne derivatives, giving 
1,2,3-triazoles as products. Although it is highly exergonic (∆Gº ≈ -255 kJ/mol), a 
high temperature is necessary to initiate the reaction (∆G‡ ≈ +108 kJ/mol)(60), and a 
mixture of both 1,4- and 1,5- disubstitue triazoles is obtained (Scheme 4.1). 
However, in the presence of copper(I), the cyclization of terminal alkyne develops 
much faster and in a regiospecific manner, giving only 4-substituted 1,2,3-triazole as 
a product(61). 
  
Scheme 4.1: Non-regiospecific Hüisgen dipolar cycloaddition. 
 
 Beside copper(I), this reaction can also be catalysed by ruthenium(II), 
Cp*RuCl(PPh3)2 for example
(62), although the ruthenium(II) catalysed reaction gives 
5-substituted triazoles. 
4.1.2 Mechanism of metal-catalyzed Hüisgen Cyclizations. 
 The mechanism of the copper(I) catalyzed Hüisgen Cyclization in case of 
terminal alkynes is represented in Scheme 4.2. Alkyne firstly forms a π complex 
with copper(I), resulting in a lowering of its pKa. After deprotonation, copper(I) 
acetylide (A) regioselectively coordinates to its azide counterpart. Intramolecular 
cyclization gives the copper(I)-coordinated 1,2,3-triazole, which is then converted to 
the 1,2,3-triazole by reprotonation. 
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Scheme 4.2: Mechanism of Cu(I)-catalyzed Hüisgen dipolar cycloaddition(61). 
 
 The ruthenium(II)-catalyzed Hüisgen cyclization is different from the 
copper(I) catalyzed one. Thus 1,4- or 1,5-disubstitued triazole can be obtained 
selectively depending upon the ruthenium(II) complex used. For example, in the 
cyclisation of benzyl azide and phenylacetylene, Ru(OAc)2(PPh3)2 give the 1,4- 
disubstituted triazole while Cp*RuCl(PPh3)2 and Cp
*RuCl(NBD) gave the 1,5- 
disubstituted cycloadduct(62). Moreover, with ruthenium(II) catalysts, internal 
alkynes could be used while the copper(I)-catalyzed only works with terminal 
alkynes. The proposed catalytic cycle of ruthenium(II) leading to the 1,5- 




Scheme 4.3: Mechanism of Ru(II)-catalyzed Hüisgen dipolar cycloaddition(62). 
 
4.1.3 Catalyst-free Hüisgen cycloadditions. 
 Hüisgen cycloaddition has been applied in a number of studies. However, one 
limitation is that it requires metal catalysis. Since these catalysts are often toxic to 
living systems, many reaction strategies have been proposed in order to achieve this 
cycloaddition process under catalyst-free conditions. 
 
4.1.3.1 Difluorinated Cyclooctynes. 
 Difluorinated cyclooctyne have been considered as an alternative alkyne for 
Hüisgen cycloadditions. Cyclooctyne is the smallest stable cycloalkyne and it is 
strained to the order of 75 kJ/mol (i.e. this is “gained” when it reacts). As a result, the 
activation energy needed to achieve cycloaddition is very low(63). Presentation of the 
two fluorines at the propargylic position makes the alkyne more electron deficient, 
increasing interaction with the electron-rich azide counterpart. By combining the two 
phenomena, ring strain and electron deficiency, difluorinated cyclooctyne can be 




Scheme 4.4: Formation of 1,2,3-triazole from difluorinated cyclooctyne and azide(60). 
 
 Due to the possibility of doing the “Click reaction” without any transition 
metal catalyst, this cycloalkyne could be used in cells. Three biotinylated derivatives 
of difluorinated cyclooctyne were incubated with cells bearing azides on their 
surfaces. After staining with FITC-labeled avidin, cells could be visualized, with the 
cyclization taking place within 60 minutes(60). 
 Although difluorinated cyclooctyne derivatives are efficient reagents for 
Hüisgen cycloaddition, their preparation is difficult and the desired compounds are 





 As a product of the Diels-Alder reaction between a furan and an alkyne, 
oxanorbornadiene also has a relatively strained ring. With the presentation of 
electron withdrawing substitutions, this bicyclic compound can also undergo 
Hüisgen cycloaddition with azides without transition metal catalysts, leading to 
trisubsitiued 1,2,3-triazoles. The mechanism represented in Scheme 4.5 shows that 
tandem [3+2] cycloaddition-retro-Diel-Alder can take place at either alkene on 
oxanorbornadiene. However, cyclization via the more electron deficient (path B) is 




Scheme 4.5: Reaction pathways for the formation of 1,2,3-triazoles from oxanorbornadiene and 
azide(64). 
 
 This strategy was applied in biological system(64). A model protein was 
functionalized with oxanorbornadiene, and then reacted with 3-azido-7-
hydroxycoumarin (without a metal catalyst) resulting in a triazole-conjugated 




Scheme 4.6: Application of the oxanorbornadiene to catalyst-free Hüisgen cycloaddition in biological 
systems. 
 
4.1.4 Applications of Hüisgen cycloadditions. 
 Due to its efficiency and user-friendliness, copper-catalysed Hüisgen 
cycloadditions have been used in various fields of chemistry from drug discovery, to 
material science. Some examples of these applications are discussed below. 
 
4.1.4.1 Multivalent carbohydrates and peptides. 
 Multivalent sugars are of synthetic interest because they can interact with 
protein partners much more strongly than monovalent ones. Dendrimeric sugars have 
been synthesised using a copper-catalyzed Hüisgen cycloaddition between alkyne 
dendrimers and azido sugars, as summarized in Scheme 4.7(65). It also demonstrates 





Scheme 4.7: Synthesis of multivalent sugars by Hüisgen cycloaddition. 
 
 In Scheme 4.7, with the same dendrimeric alkyne, azido sugars could be 
replaced with azido peptides, yielding multivalent dendrimeric peptides, that show 
enhanced biological properties compared to the original peptides(65). 
 
4.1.4.2 Cellular targeting nanoparticles. 
 “Click chemistry” has been used in applications of nanoparticle targeting in 
vivo
(66). Cyclic peptide Lyp-1 (CGNKRTGC) is a known tumor targeting peptide. It 
selectively binds to p32, a mitochondrial proteins that is both overexpressed and 
aberrantly localized at the cell surface of tumor cells, macrophages and lymphatic 
endothelial cells in certain experimental tumors and in human cancers. With the 
application of Hüisgen cycloaddition, alkyne-bearing Lyp-1 was treated with azido-
PEG bearing iron oxide nanoparticles in the presence of Cu(I) (resulting in Lyp-1 
conjugated nanoparticles (Scheme 4.8)). After injection into mice bearing human 
























































Scheme 4.8: Hüisgen cycloaddition applied for Cellular targeting nanoparticles. 
 
4.1.4.3 Synthesis of nanotubes and nanocages. 
 Hüisgen cycloaddition has been shown to be useful in creating molecular 
architectures. For instance, starting from calixarene-derivatives, cycloaddition results 
in nanotubes that can entrap gaseous molecules and metal ions. Double Hüisgen 
cycloaddition of dipropargylate calix[4]arene and diazide calix[4]arene yielded bis-




Scheme 4.9: Synthesis of bis-calix[4]arene nanotube by mean of Hüisgen cycloaddition. 
 
 By using similar reaction conditions, structures called molecular nanocages 
were achieved from polyalkyne and polyazide compounds (Scheme 4.10)(68). Once 
the first cycloaddition took place, the following reactions occured in an 
intramolecular manner. Polymerisation due to cross cycloaddition could be avoided 
by performing the reaction at high dilution. 
 
 
Scheme 4.10: Synthesis of nanocages by means of Hüisgen cycloadditions. 
 
4.1.4.4 Surface immobilisation by click sulfonamide reactions. 
 The “Click sulphonamide” reaction is a modified Hüisgen 1,3-dipolar 
cycloaddition in which sulfonylazides are used as dipolarphiles. Following liberation 
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of N2, the “Click sulphonamide” results in N-acylsulfonamides instead of 1,2,3-
triazoles. Scheme 4.11 represents a proposed mechanism of this formation(69). This 
reaction has been applied to allow immobilization of biomolecules onto glass slides. 
Following functionalisation of a glass slide with sulfonylazide, alkyne-modified 
biomolecules, including biotin, sugar and peptides were introduced and these 








































Scheme 4.11: Proposed mechanism of N-acylsulfonamide formation via Hüisgen 1,3-dipolar 




Scheme 4.12: Immobilization of biomolecules onto sulfonylazidefunctionalized glass slides. 
 
4.2 Result and Discussion. 
4.2.1 The Concept: 
 The experimental design for the search of peptide sequences as potential 
substrates for an internally promoted Hüisgen cycloaddition are summarised in 
Scheme 4.13. A PNA-encoded peptide library was generated via split-and-mix 
synthesis on PEGA resin. Each position of this tetrapeptide library was varied up to 6 
amino acids including D-Lys, D-Glu, D-Tyr, D-Pro, D-Ala and Gly and each amino 
acid was encoded with a PNA quartet. The library was functionalised with an alkyne 
on the amino terminus of the peptide chain and rhodamine B was coupled onto the 
PNA chain. After being cleaved from resin, the library was incubated with 5-
azidofluorescein. The library was then hybridised onto a DNA microarray and the 
“hit” members were then identified by fluorescence scanning. A control was 
performed under the same conditions except that copper iodide was added into the 




Scheme 4.13: Experimental procedure for screening for “peptide based” Hüisgen cycloaddition 
catalyst. 
 
4.2.2 Hüisgen cycloaddition of an alkyne modified-peptide on a solid 
support with 5-azidofluorescein. 
 In order to evaluate the Hüisgen cycloaddition between peptide sequences 
and 5-azidofluorescein and generate a control a N-5-hexynoyl-modified tetrapeptide 
of the sequence Ala-Gly-Ala-Gly was synthesised and reacted with the azido 
fluorophore. 
 5-Azidofluorescein (4.2) was prepared from 5-aminofluorescein (4.1) by a 
Sandmeyer reaction (Scheme 4.14)(71). 
 
 




 N-5-hexynoyl-modified Ala-Gly-Ala-Gly (4.3) was synthesised as shown in 
Scheme 4.15 using chlorotrityl-resin. After the coupling of 1,6-diaminohexane onto 
chlorotrityl resin, Fmoc-protected amino acids were coupled under microwave 
irradiation, giving tetrapeptide 4.4. After the Fmoc deprotection, 5-hexynoic acid 
was coupled using microwave irradiation, giving resin 4.3. 
 
Scheme 4.15: Synthesis of N-5-hexynoyl-modified Ala-Gly-Ala-Gly on chlorotrityl resin (4.3); 
Reagents and conditions: (i) 20 equiv. 1,6-diaminohexane, DCM, 2 h; (ii) Fmoc-Gly-OH; (iii) 20% 
piperidine/DMF, 2 x 10 min; (iv) Fmoc-Ala-OH or Fmoc-Gly-OH; (v) repeat (iii),(iv) as necessary; 
(vi) 5-hexynoic acid; All coupling reactions employed the following conditions: 5.0 equiv. Amino 
acids or 5-hexynoic acid, 4.8 equiv. PyBOP, 11.0 equiv. NEM/DMF, 60°C, 20 min, µw irradiation. 
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 Resin 4.3 was reacted with 5-azidofluorescein (4.2) in the presence of copper 
iodide and a catalytic amount of N,N-Diisopropylethylamine (DIPEA) (Scheme 
4.16).  
 
Scheme 4.16: Hüisgen cycloaddition of N-5-hexynoyl-modified Ala-Gly-Ala-Gly on solid support; 
Reagents and conditions: (i) 1.8 equiv. 5-azido fluorescein (4.2), 1.4 equiv. CuI, cat. DIPEA, DMF, 8 
h; (ii) 1:1 TFA:DCM, 1 h. 
 
 After 8 h. of reaction, excess reagents were washed away; the peptide 
sequence was cleaved from the solid support and analysed by analytical HPLC and 
mass spectrometry (Figure 4.1). 
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Figure 4.1: HPLC trace (A) and mass spectrum (negative scan) (B) of product from reaction between 
4.2 and 4.3. 
 
 Figure 4.1 confirmed the triazole 4.4 as the major product in the reaction. 
HPLC analysis showed a single peak whose mass corresponded to the expected 
product (found m/z = 838.3 [M-H]-, calculate m/z = 838.3 [M-H]-). 
 As a negative control, 5(6)-carboxyfluorescein was reacted with 4.3. The 
reaction was treated identically to the reaction between 4.2 and 4.3, and HPLC 
analysis and mass spectrum of reaction mixture are shown in Figure 4.2, 
representing mass corresponding to cleaved 4.3; Therefore no reaction tookplace in 
the control. 
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Figure 4.2: HPLC trace (A) and mass spectrum (positive scan) (B) of the product from reaction 
between 4.2 and 5(6)-carboxyfluorescein. 
 
 In conclusion, the alkyne-functionalized peptide and azidofluorescein could 
be used as the components in Hüisgen cycloaddition. 
 
4.2.3 Screening of a peptide library as potential substrates for internally 
promoted Hüisgen cycloaddition. 
 100 µM of library L 2.3, a peptide library functionalized with an alkyne and 
labelled with rhodamine B, in aqueous solution was mixed with 200 µM of 5-
azidofluorescein and the reaction mixture was left overnight. Unreacted 5-
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azidofluorescein was removed by a centrifugal filter device (Millipore) and the 
library was subsequently hybridised onto a DNA microarray. 
 Two controls were also performed. As a positive control (control 1), 100 µM 
(final concentration) of copper iodide was also added to the mixture and for a 
negative control (control 2), only the library solution was hybridised onto DNA 
microarrays. 
 Microarrays were scanned using a fluorescence scanner using 2 filter sets in 
order to detect two wavelengths corresponding to fluorescein and rhodamine B. In 
addition, a modified set-up was also used. In this set-up, arrays were excited at 490 
nm (fluorescein maximum excitation wavelength) and emission detected at 580 nm 
(rhodamine B maximum emission wavelength) because “hit” members would result 
in the introduction of fluorescein onto the peptide, enabling FRET. 
 “Hit” members from this screening procedure resulted in introduction of 
fluorescein onto molecules; they therefore could be identified by high fluorescein 
intensity. However, the high fluorescein intensity on the spots could be the results of 
other effects such as hybridisation efficiency. As RHOD was the internal control that 
existed within every library member (Scheme 4.13) and its intensity was not changed 
under the reaction conditions, the FLU/RHOD ratios were therefore taken into 
consideration instead of absolute fluorescein intensities. As a result, higher 
FLU/RHOD ratios would identify the “hit”. 
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Figure 4.3: Ratio of fluorescent intensities obtained from library L 2.3, treated with 5-
azidofluorescein. 
 
 Figure 4.3 shows the fluorescent intensities of library L 2.3, reacted with 5-
azidofluorescein. Both FLU and RHOD intensities were seen to vary in a wide range. 
However, most members showed relatively constant FLU/RHOD ratio (spots 
distributed on diagonal line). According to the experimental design, “hit” members 
are expected to show higher FLU/RHOD ratios due to the introduction of fluorescein 
to their peptide ends. The spots representing these peptides can be identified from 
Figure 4.3. These spots show the higher FLU/RHOD ratios than the average, and 
they are shown in the oval. 
 Data from Figure 4.3 was reploted as FLU/RHOD ratios against peptide 
sequences (Figure 4.4). It was clearly shown that, while most of library members 
have constant FLU/RHOD ratio at about 1.0, there are some members that showed 

































































































































































Figure 4.4: FAM/RHOD ratio of library L 2.3 treated with 5-azidofluorescein. 
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 Data with FLU/RHOD ratios higher than 2.0 were selected and the amino 
acid sequences were analysed by Spotfire®. From 135 sequences showing the 
highest FLU/RHOD ratios, D-Lys was a preferable amino acid at position AA1, AA2 
and AA3, D-Lys and D-Ala were preferable at position AA4. In addition, no D-Tyr 
was found at position AA1 of this group (Figure 4.5). 
 
Figure 4.5: Representation of the top 135 peptides potentially capable of promoting Hüisgen 
cycloaddition. Each panel represents the presence of a certain amino acid at each position. 
 
 However, control 1 showed very similar results despite the fact that one 
equivalent of copper iodide was added into the reaction. FLU/RHOD ratios against 
peptide sequences from this control (Figure 4.6) showed a very similar pattern as 
that in Figure 4.4. By sequence analysis (Spotfire®), similar results to those in the 
experiment were obtained (data not shown). 
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 Due to the difficulty of CuI solubilization in water, as well as 
disproportionation of copper(I), giving copper(0) and copper(II), it is possible that, in 
control 1 (the reaction mixture containing CuI), the copper(I) available in the 
reaction mixture was not sufficient. As a consequence, cycloaddition taking place in 
control 1 might be the result of the peptides’ ability to “help” the reaction. 
 Control 2 showed the same FLU/RHOD ratios for every library member 
(Figure 4.7), confirming that the increase in the fluorescein intensity as shown in 




















































































































































































































































































































































Figure 4.7: FAM/RHOD ratio of library L 2.3 (control 2).
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 FRET intensities obtained from library L 2.3 reacted with 5-azidofluorescein 
(Figure 4.8) were also analysed. “Hit” members resulted in an introduction of 
fluorescein onto the peptides and therefore acting as donor chromophore so when the 
microarrays were excited at 490 nm and emission would be detected at 580 nm with 
high intensities expected from the peptide with fluorescein conjugated. From the data 
presented in Figure 4.8, spots with highest FRET intensities were selected for amino 
acid sequence analysis (Figure 4.9). From the150 members that showed the highest 

























































































































































Figure 4.8: FRET intensity of library L 2.3 treated with 5-azidofluorescein. 
 104 
 
Figure 4.9: Representation of the peptides sequences showing high FRET intensities after Hüisgen 
cycloaddition. Each panel represents the presence of a certain amino acid at each position. 
 
 It appears that different data analysis methods gave contradictory results. 
While comparison of FLU/RHOD ratio indicated that D-Lys was a preferable amino 
acid, analysis of FRET intensities indicated that D-Glu, D-Pro and D-Tyr were 
preferable and D-Lys was the least preferable amino acid. For the FRET 
phenomenon, in addition to the existence of suitable chromophores on the analysed 
peptide sequences, the distances between both chromophores is very important. In 
library L 2.3, rhodamine B and the alkyne group are located far away from each 
other. If the cycloaddition took place, introducing fluorescein onto the peptide amino 
terminus, the FRET effect might not take place depending on the peptide 
conformation. In case of a library like L 2.3, in which chromophores are certainly not 
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in the effective range for FRET, comparison of emission intensity from each 
chromophore is the more reliable analysis method. 
4.2.4 Synthesis and evaluation of a "hit" peptide sequence as a substrate 
for internally promoted Hüisgen cycloaddition 
 From data analysis described in 2.4.3, the sequence D-Ala-D-Lys-Gly-D-Lys 
was identified as a “hit”. The N-5-hexynoyl-modified sequence was synthesised on 
aminomethyl-polystyrene resin linked by a Rink amide linker (see Figure 2.9). N-5-
hexynoyl-D-Ala-D-Lys-Gly-D-Lys-NH-Rink-PS (4.5, Figure 4.10) and was 
subjected to the solid-phase reaction with azidofluorescein (4.2) in DMF – the 
reaction conditions identical to those used in 4.2.2 except that the reaction time was 
longer (16 h). Such reaction is presented in Entry 1 of Table 4.1, while the positive 
control, where CuI was added to the reaction mixture (Entry 2 of Table 4.1), was 
also carried out.  
 
 
Figure 4.10: N-5-hexynoyl-D-Ala-D-Lys-Gly-D-Lys-NH-Rink-PS (4.5). 
 
Entry Reaction mixtures 
1 4.5 + 5-azidofluorescein (4.2, 1.8 equiv.) 
2 4.5 + 5-azidofluorescein (4.2, 1.8 equiv.) + CuI (1.4 
equiv.) + DIPEA (2 drops) 
Table 4.1: Reaction mixtures in the evaluation of “hit” peptide sequences as a substrate for internally 
promoted Hüisgen cycloaddition, using 4.5 as substrate. Reaction conditions: 16 h. in DMF. 
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 After leaving the reactions overnight, the solid support was washed and the 
peptide sequences were cleaved. The resultant residue was analysed by HPLC and 
mass spectroscopy. HPLC analysis (Figure 4.12) showed that the reaction mixture 
from entry 1 did not show the existence of any cyclo-adduct (4.6, Figure 4.11). The 
major compound found in the mixture was starting material. The product from the 
cycloaddition could be detected only in reaction from entry 2, where the Cu(I) 
catalyst was used. In this reaction, the new peak at 2.9 min was clearly detected, and 
MS analysis showed a mass corresponding to the expected product (4.6) (found m/z 
= 869.3 [M+H]+, calculate m/z = 869.4 [M+H]+). From these results, it could be 
concluded that the sequence identified as the “hit”, D-Ala-D-Lys-Gly-D-Lys, did not 
promote an internal Hüisgen cyclo-addition, despite appearing to show this on the 
array when PNA-encoded. 
 
Figure 4.11: Compound 4.6, an expected product (after cleavage) from the cycloaddition between 




Figure 4.12: HPLC analysis of reaction between 4.5 and 5-azidofluorescein without Cu(I) catalyst 
(A) and with Cu(I) catalyst (B). 
 
4.3 Conclusions. 
 In conclusions, a library of alkyne functionalized PNA-encoded D-amino 
acid-containing peptide was screened for potential substrates of self-promoting 
Hüisgen cycloaddition. Using this method the tetrapeptide D-Ala-D-Lys-Gly-D-Lys 
was identified as a peptide potentially capable of promoting a Cu(I) free Hüisgen 
cycloaddition, however, the evaluation of the self-promotion Hüisgen cycloaddition 
of such the sequence proved negative when scaled-up. This was unexpected because 
the signal of the “hit” peptide was unambiguous (FLU/RHOD ratio was as high as 
35). 
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 The results can probably be explained that the reaction conditions used in the 
screening of the library and in the evaluation of the “hit” sequence were different, 
which could affect the properties of the peptide. While the screening of the library 
took place in solution, the reaction of the “hit” sequence took place in solid phase. 
This difference might affect the accessibility of the function group on the peptide 
sequences. In addition, the library was screened in aqueous solution while the 
reaction of the “hit” was in DMF due to the resin used and the need to solubilise the 
5-azidofluorescein. 
 Having been failed in the Cu(I) free Hüisgen cycloaddition using the “hit” 
peptide sequence as substrate, the experimental procedures and data analysis were 
reinvestigated. One issue was that the library screening was not repeated to confirm 
the results (n=1). This is usually avoided because of the issue of false positives, but 
arose due to time constraints. Another possible mistake was that the screening of the 
library was carried out in aqueous solution while it should have been in a buffer 
solution. As a result, a number of library members were found to have decreased 
rhodamine B (the control) intensities after the incubation, hence mistakenly 
identified as “hit” due to the high FLU/RHOD ratios. 
 This experiment can probably be improved by doing reaction on microarray, 
in which library L 2.3 is hybridised prior to the treatment of azidofluorescein (4.2). 
By doing so, the intermolecular catalyzed reaction – where one peptide chain 
catalyzes cycloaddition on another peptide – can be avoided. Since the screening of 
this library used fluorescein derivative as a probe, it is possible that the lactone 
isomer of the dye was attacked by peptide’s nucleophilic side chain e.g. Lys, leading 
to the false positive. This problem can be avoided by using alternative dye lacking of 
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carboxylic acid such as azido derivative of Tokyo Green. In conclusions, the 
screening of library L 2.3 and the “hits” identified may be artifactual due to the 
design of the experiment. 
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Chapter 5: High-throughput screening of a PNA-encoded 
peptide library for the discovery of cell-penetrating 
peptides. 
5.1 Introduction. 
5.1.1 Structure of cell-penetrating peptides. 
 Cell-penetrating peptides (CPPs) are short peptides sequences (less than 30 
amino acids) capable of translocating across the cell membrane(72). There are a wide 
variety of existing CPP structures, however, they commonly contain positively 
charged amino acids, such as, lysine or arginine residues (Table 5.1). 
Name Sequence 
TAT peptide (48-60)(73) GRKKRRQRRRPPQ 
Penetratin(74,75) RQIKIWFQNRRMKWKK 
Peptide-based gene delivery 
systems (MPG) (76,77) 
GALFLGFLGAAGSTMGAWSQPKKKRKV 
Transportan(74,75) GWTLNSAGYLLGKINLKALAALAKKIL 
Polyarginine CPP(78,14) R8 
Table 5.1: Examples of CPP. 
 
5.1.1.1 TAT peptide (48-60). 
 TAT is an 86-amino acid protein involved in the replication of human 
immunodeficiency virus type 1 (HIV-1). This protein is able to translocate through 
the plasma membrane and reach the nucleus. The domain responsible for its cell 
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penetrating property was determined by evaluating the cellular delivery of 
derivatives of TAT-(37-60), with a sequence consisting of an α-helical domain 
(residues 37-47) and a basic domain (residues 48-60). The basic domain was found 
to play a major role in cellular delivery as an incomplete this domain resulted in the 
reduction of cell internalization efficiency(79). 
 
5.1.1.2 Penetratin. 
 Penetratin is part (residues 43–58, RQIKIWFQNRRMKWKK) of a protein 
domain that binds DNA or RNA and which first discovered in a genus of small flies 
(Drosophila)(74,75). In this peptide, 7 of the 16 residues are positively charged (Lys 
and Arg). It was found that a 16 amino acid sequence was the minimum length 
required for internalization to nerve cells. Shorter sequences were not found to have 
this property(80). 
 
5.1.1.3 Peptide-based gene delivery systems. 
 The peptide vector of the sequence GALFLGFLGAAGSTMGAWSQP 
KKKRKV was used in the delivery of oligonucletides into cells. It consists of 
hydrophobic and hydrophilic residues and rapidly delivers single and double 
stranded oligonucleotides into mammalian fibroblast cells in less than 1 h(76). 
Seventeen amino acids at the amino terminus of this vector (GALFLGFL 
GAAGSTMGA) are responsible for efficient movement across the cell membrane. 
The KKKRKV sequence is required for interaction with the nucleic acids and a 
WSQP sequence functions as the linker between the two sequences(77). The peptide 
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vector binds to oligonucleotides and the mixture forms complexes which help to 
increase the stability of the oligonucleotides by limiting access to nucleases(76). 
5.1.2.4 Transportan. 
 Transportan is a 27 amino acid peptide whose sequence was modified from 
the known CPP, galparan (GWTLNSAGYLLGPINLKALAALAKKIL)(81). Galparan 
was originally designed from the combination of 12 amino acids from the amino 
terminus of the neuropeptide galanin (GWTLNSAGYLLGPHIDNHRSFHD 
KYGLA) and mastoparan a wasp venom peptide toxin of the sequence 
INLKALAALAKKIL. Mastoparan is responsible for cell penetration while the 
amino terminal part is a galanin receptor ligand with agonistic properties. 
Transportan has been modified by replacement of proline by lysine and it was found 
to be delivered into Bowes’ melanoma cells within 1 minute(82). 
 
5.1.1.5 Polyarginines. 
 The TAT peptide (48-60) has 6 amino acids that are arginine (out of 13). This 
amino acid is therefore believed to play a critical role in cell internalizing processes. 
Polyarginine peptides were therefore evaluated as cellular delivery agents and it was 
found that a protein with a size of 29 kDa was successfully delivered into mouse 
macrophages cells by the R9 peptide. After optimization of sequence length, R6 and 
R8 were found to be the most efficient sequences for cellular delivery
(78). R3 and R7-
PNA conjugates were also synthesised and these polyarginines successfully delivered 
PNA oligomers into cells(14). 
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5.1.2 Cell-penetrating peptides - cellular uptake mechanisms. 
 The cell membrane (also called the plasma membrane, or phospholipid 
bilayer) is a physical boundary found in all types of cell responsible for isolating the 
cell content from the extracellular environment and controlling efflux/influx of 
solutes from cells. Its structure contains a wide variety of biological molecules 
including lipids, proteins and carbohydrates; however, the major component is 
phospholipids-based. A phospholipids is an amphipatic molecule consisting of a 
hydrophilic polar head in the form of a negatively charged phosphate group, and two 
hydrophobic fatty acid tails. To form the membrane, phospholipids are held together 
by non covalent interactions and arranged in a continuous double layer called the 
lipid bilayer (Figure 5.1). 
 
Figure 5.1: Phospholipid structure and cell membrane. 
 
 CPPs can access inside the cells by two distinct methods, energy-dependent 
endocytosis and energy-independent direct translocation across cell membrane(83). In 
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endocytosis, CPPs internalize into cells by encapsulation into lipid vesicles 
(liposomes), which are internalized after resealing of the cell membrane. Opening of 
the liposome results in releasing of CPPs into the cytoplasm. 
 CPPs’ direct translocation was proposed due to fact that some CPPs cross 
the cell membrane in an energy-independent process. There are a few different types 
of structure formed, namely inverted micelles, barrel-staves, and “carpets” (Figure 
5.2)(83). In an inverted micelle(84), positively charged cell-penetrating peptides firstly 
interact with negatively charged phospholipids at the cell membrane which induces 
the formation of a cavity with the CPPs inside. A hydrophobic outer shell makes an 
inverted micelle possible to move across the membrane’s hydrophobic core. It then 
releases the CPPs (and their binded cargos) into the cytoplasm and becomes part of 
the cell membrane. The Barrel-stave model(85) is a membrane disintegration 
mechanism, involving three steps. In the first step, peptides bind to the membrane by 
electrostatic interactions. Next, these peptides insert into the lipid bilayer. Finally, the 
peptides aggregate into a barrel-like structure in which hydrophilic side chains are 
pointed toward a central aqueous pore while their hydrophobic parts interact with 
lipid in the cell membrane. This aqueous pore increases in diameter through the 
progressive recruitment of additional monomers. The Carpet model(85) originated 
from cellular translocation of antimicrobial peptides. In this mechanism, CPPs bind 
to the plasma membrane in the orientation parallel to the surface and self-associate 
with other chains in a carpet-like manner. While its positive side chains stick at the 
negatively charged phosphate head group, peptide hydrophobic backbones are 
embedded into the lipid layer of the target cell, perturbing the structural organization 
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of the membrane. Therefore, peptide that accumulates outside can cross the cell 
membrane via this weakened spot. 
 
Figure 5.2: peptide-phospholipid arrangements in the inverted micelle (A)(84), the barrel-stave (B)(85) 
and the carpet mechanism (C)(85). 
 
5.1.3 Applications of cell-penetrating peptides. 
5.1.3.1 Drug delivery. 
 One of the challenges in drug design is the application of a suitable delivery 
method so that it can be fully effective. For example, cyclosporin A, a cyclic peptide 
drug used against inflammatory skin diseases, is effective via oral administration but 
with a number of side effects, while direct application on the skin is ineffective due 
to poor dermal absorption. However, conjugation of a hepta-D-arginine transporter to 







































Figure 5.3: hepta-D-arginine-cyclosporin A conjugate. 
 
5.1.3.2 Nucleic acid delivery. 
 In gene therapy, insertion of highly negatively charged DNA or RNA into a 
target cell is inefficient. The TAT peptide was found to be able to form complexes 
with plasmid DNA and therefore carries them into various types of cell via 
endocytosis while siRNAs could be delivered by MPG and polyarginine(87). Peptide 
nucleic acids (PNAs), unlike DNA or RNA, contain a neutral peptide backbone but 
their translocation across plasma membrane is problematic. By conjugating to 
transportan, a 16-mer PNA could be delivered into HeLa cells(88), while R9 has also 
been demonstrated to enable PNA delivery(14). 
 
5.1.3.3 Imaging agent delivery. 
 Visualization of internal features and the structure of living organisms is 
important in biological studies. While molecular fluorophores are efficient tool for 
such studies, their poor cellular uptake is problematic. CPPs could be used to 
conjugate with dyes to improve their cellular uptake. Applications of selectively 
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labelling cancer cells has been presented(89). In addition to binding to a fluorophore, a 
cationic cell-penetrating peptide sequence was linked with an anionic tail by a 
cleavable linker. The anionic region acts as an inhibitor of the CPP to cross the cell 
membrane. In the presented case, an enzyme on the tumor cell, cleaving the anionic 
region allowed the positively charged cell-penetrating sequence to translocate into 
the cancer cell, therefore allowing the cancer cells to be identified (Figure 5.4). 
 
Figure 5.4: Cancer cell identification by protease- triggered CPP release. 
 
5.1.3.4 Protein and macromolecule delivery. 
 The development of peptide-drugs and therapeutic proteins are often limited 
by the poor permeability of the cell membrane. However, CPPs can be used as one of 
the solutions for cellular protein delivery. Pep-1, (KETWWETWWTEWSQP 
KKKRKV) is an example of a CPP capable of delivering peptides and proteins into 
cells(90). Its tryptophan rich region (KETWWETWWTEW) allows hydrophobic 
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interactions with delivered proteins while the lysine rich motif (KKKRKV) is 
responsible for membrane crossing. Pep-1 has been used for the delivery of 
macromolecules including proteins(91,92) peptides(93) and antibodies(94) into various 
types of cell. 
5.2 Results and Discussion. 




 The procedure for the screening of PNA-encoded peptide library for potential 
cell-penetrating peptides is summarised in Scheme 5.1. A subset of library L 2.4 
(AA4 = Pro) was added to a mammalian cell culture and incubated for 4 h. The media 
was then removed and the cells were washed before they were lysed. Members of the 
subset of library L 2.4 that were delivered into cells (termed here L 2.4*) were 
purified by filter-centrifugation. Purified library members were hybridised onto a 
DNA microarray containing complementary DNA oligos to all members of library L 
2.4. The sequences of L 2.4* which were taken up by cells were then identified 
following fluorescence scanning. 
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Scheme 5.1: Method for the screening of library L 2.4(95). 
 
5.2.2 Synthesis of N-(6-aminohexyl)glycine tetramer-PNA oligo-conjugate 
control. 
 A peptoid consisting of repeating N-(6-aminohexyl)glycine units (also known 
as lysine-like peptoid monomer, Llp) has been shown to be an efficient carrier for 
cellular delivery(96) and this peptoid was used as a control. A N-(6-
aminohexyl)glycine tetramer-PNA oligo conjugate (5.1, Figure 5.6) was initially 
synthesised and delivered into cells. In this compound, N-(6-aminohexyl)glycine 
repeating unit acted as the cellular delivering component, while the PNA 12-mer and 
FAM were in essence the cargo. 
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Figure 5.6: N-(6-aminohexyl)glycine tetramer-PNA oligo conjugate (5.1). 
 
 The synthesis of compound 5.1 is summarised in Scheme 5.2. It began by the 
coupling of Fmoc-Lys(Dde)-OH (2.19) to H-Rink-PEGA resin, giving rise to resin 
2.22, which was coupled four times to [(6-tert-Butoxycarbonylamino-hexyl)-(9H-
fluoren-9-yl methoxycarbonyl)-amino]-acetic acid (5.2, Figure 5.7). The resulting 
resin (5.3) was coupled to Dde-PNA monomers until the required length of PNA 
oligomer (12-mer) was reached (5.4). After the removal of the Fmoc group, the free 
amino group was acetylated with acetic anhydride (5.5). An Fmoc-Ahx-OH spacer 
was coupled to the PNA oligo, followed by the removal of the Fmoc group and 
labelling with FAM (5.7) 
 












































Scheme 5.2: Synthesis of N-(6-aminohexyl)glycine tetramer-PNA oligo conjugate on solid support; 
Reagents and conditions: (i) 2.19; (ii) 20% piperidine / DMF, 2 x 10 min; (iii) 5.2; (iv) repeat (ii),(iii) 4 times; (v) 
NH2OH·HCl/imidazole, 1 h; (vi) Dde-PNA-OH; (viii) repeat (vi),(vii) 12 times; (viii) 1:1 (v/v) Ac2O:Py, 1.5 h; 
(ix) Fmoc-Ahx-OH; (x) 5(6)-carboxyfluorescein; (5.0 equiv. amino acids, PNA monomers or dye, 4.8 equiv. 
PyBOP, 11.0 equiv. NEM/DMF, 60°C, 20 min, microwave irradiation). 
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 After cleavage by a mixture of TFA:TIS:DCM (90:5:5) (Scheme 2.13), the 
N-(6-aminohexyl)glycine tetramer-PNA oligo conjugate (5.1, Figure 5.6) was 
obtained by precipitation. 




 Solutions of 5.1 (1, 2, 4, 6, 8 and 10 µM) were added to HeLa cells, grown to 
90% confluency. After 4 h of incubation, cells were washed and analysed by Flow 
cytometry. The mean fluorescence of 10,000 cells was recorded and compared with 
untreated cells. The relationship between fluorescent intensity and concentration of 
5.1 is shown in Figure 5.8. 
                                                 
1 Sections 5.2.3, 5.2.4 and 5.2.5 are in collaboration with Nina Svensen 
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Figure 5.8: Fluorescent intensities of cells after incubation with different concentrations of 5.1. 
 
 Figure 5.8 shows that the mean fluorescence of cells incubated with 
compound 5.1 correlated with the concentration of 5.1. It can be concluded that, 
upon incubation for 4 h, N-(6-aminohexyl)glycine tetramer-PNA oligo conjugate 
(5.1) was delivered into HeLa cells. 
5.2.4 Cellular delivery of an encoded library into HeLa cells. 
 A solution of a subset of L 2.4 [AA4 = Pro (125 members) (collective 
concentration 100 µM)] in RPMI media was incubated with HeLa cells grown to 
80% confluency for 2 h. After incubation, cells were washed and lysed and the 
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solution obtained from cells was purified by filter-centrifugation (Millipore, 3,000Da 
and 10,000Da molecular weight), giving a “cell solution” containing library 
members that had entered the cells (referred as L 2.4* in Scheme 5.1). This solution 
was then hybridised onto a DNA microarray and scanned using the filter set for the 
detection of FAM. 12 peptide sequences showing the highest fluorescent intensities 







































































Figure 5.9: Top peptide sequences delivered into HeLa cells using library L 2.4. 
 
 Three of the top four sequences contained Cys at the position AA1 suggesting 
that this amino acid is important at this position. Of the top twelve sequences, Tyr 
was the amino acid most often found at position AA3 while at position AA2, no 
consensus amino acid was found. The consensus “hit” sequences for the cellular 
delivery of HeLa cells was Pro-Tyr-Yyy-Cys (Yyy represents any amino acid). In 
addition, Pro-Pro was found four times in the top twelve and is thus a possible 
peptide sequence delivered to this cell line. 
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5.2.5 Cellular delivery of an encoded library into B16F10 cells. 
 Cellular incubation, purification and analysis of the subset of library L 2.4 
[AA4 = Pro (125 members)] was carried out as described above with B16F10 cell 
and the 12 peptide sequences having the highest fluorescent intensities are 





































































Figure 5.10: Top peptide sequences of L 2.4 delivered into B16F10 cells. 
 
 From the delivery of the subset of library L 2.4 into B16F10 cells, the top two 
peptide sequences showed higher efficiency than other sequences and these two 
sequences have common amino acids, which are Pro, Tyr and Cys at position AA4, 
AA3 and AA1 respectively. In addition, Tyr was found at position AA3 in 8 of the top 
twelve sequences therefore the consensus “hit” sequences for the cellular delivery 
into B16F10 cells are identical to those for HeLa cells, which is Pro-Tyr-Zzz-Cys 
where Zzz represents any amino acid. However, in the case of B16F10 cells, the 
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sequence containing Llp (represented as “X” in Figures) at position AA2 were 
preferred. 
5.2.6 Synthesis and cellular delivery of the “hits” from the library screen. 
 A fluorescent-labeled tetrapeptide (FAM-Ahx-Pro-Tyr-Llp-Cys-NH2, 5.8) 
whose sequence was determined from the screening of the libraries was synthesised 
by solid-phase synthesis as well as a control (FAM-Ahx-Pro-Gly-Ala-Glu-NH2, 5.9), 
which was a negative peptide from the library (Figure 5.11). Both peptides were 













































Peptide 5.9  
Figure 5.11: Peptide sequences used in evaluation of cellular delivery; consensus “hit” from library 





5.2.6.1 Cellular delivery of peptide 5.8 and 5.9 into HeLa cells. 
 Solutions of peptide 5.8 and peptide 5.9 were added to the growing media 
(100 µM). Cells were incubated at 37ºC, 5% CO2 for 2 h. Cells were detached by 
trypsination and 0.2% trypan blue added (quenched extracellular fluorescene). 
Samples were analysed by flow cytometry (using a BD Biosciences FACSDiva and 
software). Untreated cells were defined as having 0% uptake and the results are 
shown in Figure 5.12. 
 
Figure 5.12: Cellular deliveries of peptides 5.8 and 5.9 into HeLa cells. 
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5.2.6.2 Cellular delivery of peptide 5.8 and 5.9 into B16F10 cells. 
 Cellular delivery into B16F10 cells was carried out as described above and 
the result is shown in Figure 5.13 
 
 
Figure 5.13: Cellular deliveries of peptides 5.8 and 5.9 into B16F10 cells. 
 
 While peptide 5.8 was found to be delivered into both cell lines, the negative 
control (peptide 5.9) gave the same results. Therefore the experiments were repeated 
with reduced concentrations of peptides (10 µM). The result of this experiment with 
B16F10 cells is shown in Figure 5.14 
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Figure 5.14: Cellular deliveries of peptides and fluorescein at different concentrations into B16F10 
cells [numbers in the blankets indicate the concentrations (µM)]. 
 
 As shown in Figure 5.14, the reduced concentration of peptides resulted in a 
lower uptake %, however, peptide 5.9 (negative control) was still found to be 
delivered better than peptide 5.8 (the “hit”). 
 
5.2.6.3 Cellular delivery of peptide 5.8 and 5.9 into HeLa cells and comparison with 
known delivering agents. 
 FAM-labeled N-(6-aminohexyl)glycine tetramer, FAM-labeled N-(6-
aminohexyl)glycine nonamer (both known CPPs), peptide 5.8 and peptide 5.9, were 
delivered into HeLa cells in order to compare the delivering efficiency. All 
compounds were incubated with the cells at 10 µM concentration and the uptake % 
in each case was recorded at 2 h, 4 h and 24 h as shown in Figure 5.15 
 130 
 
Figure 5.15: Cellular deliveries of N-(6-aminohexyl)glycine polymers and peptides into HeLa cells at 
different times. 
 
 The results in Figure 5.15 show that both peptides (5.8 and 5.9) have a cell 
delivering ability since the cellular uptakes of these peptides were almost complete at 
24 h. However, in comparison with N-(6-aminohexyl)glycine polymers, peptide 5.8 
and peptide 5.9 entered cells at lower rate. 
5.3 Conclusions. 
 In conclusion, a PNA 12-mer as a possible cargo can be delivered into cells 
by a tetrapeptide CPPs. A PNA-encoded tetrapeptide library was screened for novel 
CPPs. The “hit” sequences for the delivery into two cell lines (HeLa and B16F10) 
were found to be identical at three positions (Pro-Tyr-Zzz-Cys where Zzz represents 
any amino acid) therefore the second amino acid from the carboxyl terminus (AA2) 
might be less important in the cellular delivery process. 
 The sequence of the control (peptide 5.9) was obtained from a negative 
member of the library and was expected to be a lower efficiency cellular delivering 
agent than 5.8. The rationale for this is that the library used as substrate in the 
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screening was too small, consisting of only 125 members. It is possible that all 
members in this library have delivery potential, therefore peptide 5.9, which had one 
of the lowest efficiencies of the 125 compound library was still a good delivery 
agent. In addition, a cargo to be delivered by single peptides (peptides 5.8 and 5.9) 
was smaller compared to that delivered by library members (a fluorescein amide 
versus fluorescein-labelled PNA oligomer respectively), as a result, the delivery by 
peptide 5.9 was found in high efficiency despite the fact that it showed a poor 
delivery efficiency in library screening. Therefore, the cargo used in the evaluation 
of single peptide as delivery agent should have been designed to be identical to that 
in the library. 
 132 
Chapter 6: Experimental Section 
6.1 General section. 
6.1.1 General information. 
 All solvents and reagents were obtained from commercial suppliers and used 
without purification, unless otherwise stated. All amino acid derivatives were 
obtained from GL Biochem (China)  
 NMR spectra were recorded on a Bruker ARX-250 at 250 MHz for 1H and 
62.5 MHz for 13C in the solvents indicated. All chemical shifts (δ) are quoted in ppm 
using the residual non-deuterated solvent as the internal standard or the 13C natural 
abundance of the deuterated solvent. Coupling constants (J) are reported in Hz. 
 Infrared (IR) spectra were obtained on a Fourier transform IR Bruker Tensor 
27 Spectrometer (FTS) fitted with a Specac single reflection diamond attenuated total 
reflection (ATR) Golden Gate. All samples were analysed neat and frequencies are 
reported in cm-1 and only frequencies corresponding to significant functional groups 
are reported. 
 Aluminium backed silica plates (Merck silica gel 60 F254) were used for thin 
layer chromatography (TLC) to monitor solution-phase reactions. TLC visualisation 
was carried out using short wavelength ultraviolet (UV) light (254 nm). Flash 
column chromatography was performed on silica gel using Keiselgel 60, 230-400 
mesh (supplied by Merck). 
 Microwave reactions were carried out in an Initiator™ single-mode 
microwave from Biotage (Sweden). HPLC analysis was carried out on an Agilent 
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Technologies 1100 Chemstation, eluting with (A) H2O/0.1% TFA and (B) 
CH3CN/0.04% TFA at a flow rate of 1 mL/min, with a gradient of 5 to 95% B over 6 
min, holding at 95% B for 3 min. The columns used were Discovery C18 from 
Supelco (50 mm x 4.6 mm, 5 µm), a Luna C18 from Phenomenex (150 mm x 4.6 
mm, 5 µm) or a Gemini C18, 110 Å from Phenomenex (100 mm x 4.6 mm, 5 µm). 
Electrospray ionization mass spectrometry (ESI–MS) analysis was carried out on an 
Agilent Technologies LC/MSD Series 1100 quadrupole mass spectrometer (QMS) in 
ESI mode. 
 Semi-preparative reverse-phase HPLC was performed on an Agilent 1100 
system equipped with a Phenomenex Prodigy C18 reverse-phase column (250 x 10 
mm, 5 µm) with a flow rate of 2.5 mL/min and eluting with 0.1% TFA in H2O (A) 
and 0.042% TFA in acetonitrile (B), with an initial isocratic period of 4 min at 0% B 
followed by a gradient of 0 to 50% B over 25 min and 50 to 100% B over 10 min, 
holding at 100% B for 5 min. 
 
6.1.2 General experimental procedures. 
6.1.2.1 Qualitative nynhidrin test.
(97)
 
 To a few resin beads placed in a small test tube were added 3 drops of reagent 
A and 1 drop of reagent B. The mixture was heated at 100°C for 5 min. The presence 
of resin bound free amine was indicated by a blue colour. 
Reagent A: Solution 1: Potassium cyanide (65 mg, 1 mmol) was dissolved in H2O 
(100 mL). An aliquot of this solution (2 mL) was diluted with freshly distilled 
pyridine (98 mL). Solution 2: Phenol (40 g, 420 mmol) was dissolved in absolute 
EtOH (10 mL). Solutions 1 and 2 were mixed together to give reagent A. 
 134 
Reagent B: Ninhydrin (2.5 g, 14 mmol) was dissolved in absolute EtOH (50 mL). 
 
6.1.2.2 Fmoc deprotection. 
 To a resin (1 g), pre-swollen in DMF for 10 min, was added a solution of 
20% piperidine in DMF (20 mL), and the mixture was shaken for 10 min. The resin 
was washed with DMF (3 x 25 mL) and the deprotection procedure was repeated. 
The resin was washed with DMF (3 x 25 mL) and DCM (3 x 25 mL). 
 
6.1.2.3 Dde deprotection. 
 NH2OH·HCl (6.25 g, 9 mmol) and imidazole (4.59 g, 6.75 mmol) were added 
to 25 mL of NMP and the mixture was sonicated until complete dissolution. Just 
before reaction, 5 volumes of this solution were diluted with 1 volume of DMF. The 
solution was added to the resin and the resulting mixture was shaken for 1 h for 
PEGA resin and 3 h for PS resin at room temperature. The resin was finally washed 
with DMF (3 x) and DCM (3 x). 
 
6.1.2.4 Fmoc-amino acid and Dde/Mmt-protected PNA monomers couplings 
(Method 1). 
 Fmoc-amino acids or Dde/Mmt-protected PNA monomers (5 eq), PyBOP 
(4.8 eq) were dissolved in DMF (0.1 M) followed by the addition of NEM (11 eq). 
The resulting solution was mixed for 10 sec. before adding to the PEGA resin (1 eq) 
pre-swollen in DMF and the coupling was performed under microwave irradiation at 
60ºC for 20 min. Resins were washed with DMF (3 x), DCM (3 x), MeOH (3 x) and 
DCM (3 x). 
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 Fmoc-amino acids or Dde/Mmt-protected PNA monomers (4 eq), HOBt (4 
eq) and DIC (4 eq) were dissolved in DMF (0.1 M). The resulting solution was 
mixed for 15 min. before adding to the PEGA resin (1 eq) pre-swollen in DMF and 
the coupling was performed under microwave irradiation at 60ºC for 20 min. Resins 
were washed with DMF (3 x), DCM (3 x), MeOH (3 x) and DCM (3 x). 
 
6.1.2.6 Cleavage of libraries from the resin. 
 Each library was cleaved from the resin (5 g) using a mixture of 
TFA/TIS/DCM (90/5/5) (1 mL) for 1 h and precipitated with cold diethyl ether. The 
precipitate was collected by centrifugation and dried in vacuo for 2 h to afford library 
as a solid. 
 
6.2 Experimental to Chapter 2. 





 To a mixture of DCC (75 g, 356 mmol), DMAP (4.4 g, 35.6 mmol) and acetic 
acid (40.8 mL, 712 mmol) in DMF (580 mL) was added dimedone (50 g, 356 mmol) 
for 36 h. Precipitated dicyclohexylurea (DCU) was removed by filtration and the 
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filtrate was concentrate in vacuo, taken up in water (300 mL) and extracted with 
EtOAc (300 mL). The organic layer was washed with 1 M aqueous KHSO4 (3 x 100 
mL), 10 % aqueous NaHCO3 (3 x 100 mL) and brine (1 x 100 mL). The organic 
phase was dried over MgSO4 and concentrated in vacuo to afford 2.3 as a mixture of 
brown oil/yellow solid (58.3 g, 90%). 
 
HPLC: tR = 4.4 min (66% purity, 254 nm). 
ESI
+
/MS: m/z (%) 183.1 [M+H]+ (100). 
1
H NMR (250 MHz, CDCl3) δ = 2.59 (3H; s, CH3), 2.52 (2H; s, CH2), 2.35(2H; s, 
CH2), 1.06 (6H, s, C(CH3)2). 
13
C NMR (62.5 MHz, CDCl3) δ = 202.4 (C), 197.9 (CO), 195.1(CO), 112.3 (C), 52.4 






 Ethylenediamine (2.4) (140 mL, 2.13 mol) was stirred at 4 °C while 2-
chloroacetic acid (2.5) (20 g, 213 mmol) was added portionwise. The reaction was 
then stirred for 12 h. Excess (2.4) was evaporated in vacuo at 60 °C (higher 
temperature led to decomposition) to give an oil that was triturated with DMSO (500 
mL). The resulting white solid was collected by filtration, washed with DMSO (3x 
100 mL) and Et2O (3 x 100 mL) before being dried in vacuo at 40 °C for 24 h to give 






/MS: 192.1 [M+H]+ (28), 214.0 [M+Na]+ (100). 
1
H NMR (250 MHz, D2O) δ =3.24 (2H, s, CH2CO), 3.00 (2H, t, J = 6.3 Hz, 
CH2NH), 2.87 (2H, t, J 6.3 Hz, NH2CH2). 
13
C NMR (62.5 MHz, D2O) δ = 178.2 (CO), 51.6 (CH2), 46.5 (CH2), 38.5 (CH2). 





 To a stirred suspension of 2.6 (14.2 g, 120 mmol) in MeOH (450 mL) at 0°C 
was added SOCl2 (43.5 mL, 600 mmol). The reaction was refluxed for 12 h before 
cooling to 0°C to give 2.7 as an off-white solid which was collected by filtration, 
washed with a mixture of MeOH:DCM (1:1) and Et2O and dried in vacuo at 40 °C 
for 24 h. The product (20.8 g, 85%) was used without further purification. 
 
HPLC: tR = 0.7 min (100% purity, ELSD). 
ESI
+
/MS: m/z (%) 133.1 [M+H]+ (100). 
1
H NMR (250 MHz, D2O) δ = 4.11 (2H, s, CH2CO), 3.83 (3H, s, CH3), 3.54-3.39 
(4H, m, 2 x NCH2). 
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 To a stirred solution of diamine salt (2.7) (41.6 g, 203 mmol) and DIPEA (71 
mL, 406 mmol) in 1:1 DCM:MeOH (v/v) (500 mL) was added Dde-OH (2.3) (48.1 
g, 264 mmol). The solution was stirred for 16 h before evaporation of the solvent in 
vacuo. The crude material was taken up in EtOAc (400 mL) and extracted with 1 M 
KHSO4 (3 x 100 mL). The aqueous solution was treated with NaHCO3 until the pH 
was 9 before extraction with further EtOAc (3 x 100 mL). The organic phase were 
combined, washed with brine (1 x 100 mL), dried over MgSO4 and concentrate in 
vacuo to give 2.8 (36.0 g, 60%) as a brown oil. 
 
HPLC: tR = 2.5 min (96% purity, ELSD). 
ESI
+
/MS: m/z (%) 297.2 [M+H]+ (100). 
1
H NMR (250 MHz, CDCl3) δ = 3.72 (3H, s, OCH3), 3.47 (4H, m, 2 x NCH2), 2.93 
(2H, t, J = 6.1 Hz, NHCH2CO), 2.56 (3H, s, CCH3); 2.35 (4H, s, 2 x CH2-Dde), 2.03 
(1H, br s, NH), 1.01 (6H, s, (CH3)2-Dde). 
13
C NMR (62.5 MHz, CDCl3) δ = 197.3 (CO), 173.1 (C), 172.4 (CO), 107.6 (C), 














 To a suspension of thymine (2.9) (10.0 g, 79.3 mmol) and K2CO3 (10.96 g, 
79.3 mmol) in DMF (240 mL) was added methyl bromoacetate (7.35 mL, 79.3 
mmol), and the mixture was stirred vigorously overnight under N2. The reaction 
mixture was filtrated and evaporated to dryness in vacuo. The solid residue was 
cooled to 0°C, treated with water (80 mL) and 4 M HCl (aqueous, 4 mL), and stirred 
for 30 min. The precipitate was collected by filtration and washed with water (3 x 40 
mL). The precipitate was treated with water (80 mL) and 2 M NaOH (aqueous, 40 
mL) and boiled for 10 min. The mixture was cooled to 0°C, treated with 4 M HCl 
(aqueous, 30 mL), and stirred for 30 min. The white precipitate was collected by 
filtration, washed with water (3 x 10 mL), and dried over P2O5 in vacuo for 16 h, 
giving thymin-1-yl acetic acid (2.10) (8.23 g, 56%) as a white solid. 
 
HPLC: tR = 1.3 min (100% purity, ELSD). 
ESI
-
/MS: m/z (%) 183.1 [M-H]- (100). 
1
H NMR (250 MHz, d6-DMSO) δ = 11.34 (1H, br s, NH), 7.49 (1H, s, CH), 4.36 
(2H, s, CH2), 1.75 (3H, s, CH3). 
13
C NMR (62.5 MHz, d6-DMSO) δ = 169.6 (CO), 164.3 (CO), 151.0 (CO), 141.7 













 Cytosine (2.11) (1.11 g, 10 mmol) and Mmt-Cl (4.63 g, 15mmol) were 
suspended in pyridine (50 mL) and, after the addition of 4-ethylmorpholine (1.55 g, 
10 mmol), this mixture was briefly heated to 45°C and stirred overnight. Water (50 
mL) was added to the stirred suspension followed by DCM (30 mL) and the resulting 
precipitate 1.14 g (30%) was collected by filtration and used in the next reaction 
without further characterization. 
 
HPLC: tR = 4.4 min (100% purity, ELSD). 
ESI+/MS: m/z (%) 273.0 [Mmt]+ (100), 789.2 [2M+Na]+ (22) 
No NMR spectrum was recorded since the named compound 2.12 was insoluble in 
















 NaH (60% in mineral oil, 104 mg, 2.6 mmol) was added to a stirred 
suspension of 4-{[(4-methoxyphenyl)(diphenyl)methyl]amino}-2(1H)-pyrimidinone 
(2.12) (1.0 g, 2.6 mmol) in DMF (10 mL). After stirring for 1 h, the mixture was 
cooled to 0°C and methyl bromoacetate (0.3 mL, 3.13 mmol) was added dropwise. 
The reaction was stirred for 16 h before evaporation of the solvent in vacuo. The 
resulting oil was precipitated with H2O and collected by filtration, and washed with 
water to give methyl (4-{[(4-methoxyphenyl)(diphenyl)methyl]amino}-2-oxo-1(2H)-
pyrimidinyl) acetate as a white solid which was dried over P2O5 in vacuo. 
 Methyl (4-{[(4-methoxyphenyl)(diphenyl)methyl]amino}-2-oxo-1(2H)-
pyrimidinyl) acetate (1.4 g, 7.6 mmol) was suspended in 2 N aqueous NaOH (5 mL) 
and the mixture was stirred for 2 h at reflux. The reaction mixture was cooled to 
room temperature, washed with DCM (3 x 10 mL) and acidified with 2 N aqueous 
HCl until pH 2. The precipitate was collected by filtration, washed with water (3 x 10 
mL) until the filtrate was neutral and dried in vacuo for 16 h to give 2.13 (1.04 g, 
91% over 2 steps) as a white solid. 
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HPLC: tR = 4.6 min (80% purity, ELSD). 
ESI
-
/MS: m/z (%) 454.0 [M-H]- (100). 
1
H NMR (250 MHz, d6-DMSO) δ = 8.40 (1H, br s, NH), 7.46 (1H, d, J = 6.8 Hz, 
CH-Cyt), 7.40-7.03 (12H, m, CH-Mmt), 6.84 (2H, d, J = 8.5 Hz, CH-Mmt), 6.20 
(1H, d, J = 6.8 Hz, CH-Cyt), 4.33 (2H, s, CH2), 3.72 (3H, s, CH3O-Mmt), 3.61 (3H, 
s, OCH3). 
13
C NMR (62.5 MHz, d6-DMSO) δ = 169.1 (CO), 164.0 (C), 157.4 (C), 154.5 (CO), 
148.8 (C and CH), 136.7 (C), 129.9 (CH), 128.5 (CH), 127.4 (CH), 126.1 (CH), 












 Adenine (2.14) (10.0 g, 74 mmol) was suspended in dry DMF and sodium 
hydride (60% in mineral oil, 2.14 g, 89 mmol) was added portionwise with stirring. 
The reaction mixture was stirred for 2 h at room temperature. Subsequently, methyl 
bromoacetate (13.90 mL, 150 mmol) was added dropwise. After an additional 2 h of 
stirring, the solvent was removed by evaporation in vacuo. The remaining oil was 
shaken with water (100 mL). The solid was collected by filtration and washed with 
water (2 x 50 mL) than EtOH (2 x 50 mL) to give 8.60 g (56%) of 2.15 as white 
crystals. 
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HPLC: tR = 0.8 min (100% purity, ELSD). 
ESI
+
/MS: m/z (%) 208.1 [M+H]+ (100). 
1
H NMR (250 MHz, d6-DMSO) δ = 8.12 (1H, s, CH), 8.11 (1H, s, CH), 7.30 (2H, s, 
NH2), 5.08 (2H, s, CH2), 3.70 (3H, s, CH3). 
13
C NMR (62.5 MHz, d6-DMSO) δ = 168.4 (CO), 155.9 (CNH2), 152.5 (CH), 149.5 













 A mixture of ester 2.15 (3.1 g, 15 mmol), NEM (1.9 mL, 15 mmol) and 4-
monomethoxytrityl chloride (6.95 g, 22.5 mmol) in 1:1 pyridine:DCM (100 mL) was 
heated at 40ºC for 3 h, then 25ºC for 16 h. After evaporation of the solvents in vacuo, 
the residue was re-dissolved in EtOAc (200 mL), and the organic layer were washed 
with 1 N aqueous KHSO4 (50 mL), 10% aqueous NaHCO3 (50 mL), brine (50 mL), 
and dried over MgSO4. After evaporation of the solvent in vacuo, the residue was 
washed with petroleum ether (100 mL) to give a yellowish oil (7.42 g). The product 
was used without further purification. 
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 Methyl (6-{[(4-methoxyphenyl)(diphenyl)methyl]amino}-9H-purin-9-yl) 
acetate (3.18 g, 6.62 mmol) was refluxed for 2 h in 1 N aqueous NaOH (100 mL) and 
stirred at 25°C for 2 h The solution was cooled to 0°C. Following the addition of 1 N 
aqueous KHSO4 (60 mL), the mixture was stirred at 0°C for 30 min, giving rise to 
the precipitation of 2.16. After filtration, the residue was washed with small amount 
of water (30 mL) until the filtrate was neutral and dried in vacuo for 12 h to give 2.16 
(3.05 g, 99% over 2 steps) as a white solid. 
 
HPLC: tR = 5.2 min (100% purity, ELSD). 
ESI
-
/MS: m/z (%) 464.1 [M-H]- (100). 
1
H NMR (250 MHz, d6-DMSO) δ = 8.20 (1H, s, CH-pur), 7.91 (1H, s, CH-pur), 
7.38-7.16 (12H, m, CH-Mmt), 6.85 (2H, d, J = 8.9 Hz, CH-Mmt), 4.97 (2H, s, CH2) 
3.71 (3H, s, CH3O-Mmt). 
13
C NMR (62.5 MHz, d6-DMSO) δ = 169.2 (CO), 157.6 (C), 153.4 (C), 151.2 (CH), 
148.8 (C), 145.1 (C), 141.9 (CH), 137.0 (C), 129.8 (CH), 128.4 (CH), 127.6 (CH), 









 Compound 2.8 (8 g, 27 mmol) was added to a mixture of compound 2.10 (5 
g, 27 mmol), DCC (6.6 g, 32 mmol) and HOBt (4.1 g, 27 mmol) in DMF (125 mL). 
The mixture was stirred for 16 h and DCU was removed by filtration. DMF was 
evaporated in vacuo and the residue was re-dissolved in DCM (300 mL), filtered and 
the filtrate was washed with 1 N KHSO4 (150 mL), 10% NaHCO3 (150 mL) and 
evaporated to dryness. The residue was purified by column chromatography, eluting 
with 5% MeOH/DCM to give 2.17 T as a white solid (11.5 g, 92%). 
 
HPLC: tR = 3.2 min (100% purity, ELSD). 
ESI
+
/MS: m/z (%) 463.3 [M+H]+ (100). 
1
H NMR (250 MHz, d6-DMSO) two rotamers: δ = 13.20 and 13.13 (1H, br s, 
NHDde), 11.32 and 11.30 (1H, br s, NH), 7.33 and 7.31 (1H, s, CH-Thy), 4.67 and 
4.51 (2H, s, CH2COO), 4.41 and 4.11 (2H, s, CH2CO), 3.72 and 3.62 (3H, s, OCH3), 
3.69 (2H, br s, CH2N), 3.53 (2H, br s, CH2N), 2.53 and 2.47 (3H, s, CH3C-Dde), 2.30 
and 2.27 (4H, s, CH2-Dde), 1.75 (3H, s, CH3), 0.95 and 0.94 (6H, s, (CH3)2-Dde). 
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13
C NMR (62.5 MHz, CDCl3) two rotamers: δ = 174.0 and 173.7 (CO), 169.3 and 
169.1 (CO), 168.0 and 167.2 (CO), 164.0 and 163.9 (C), 151.1 and 151.0 (CO), 
141.1 and 140.8 (CH), 110.8 and 110.7 (C), 108.4 and 108.3 (C), 53.1 and 52.6 
(CH3), 50.5 (CH2), 48.4 and 48.2 (CH2), 47.9 (CH2), 47.6 (CH2), 47.3 (CH2), 41.2 




















 Compound 2.17 C was synthesised from 2.13 (5 g, 11.3 mmol) in analogy to 
2.17 T and obtained as a white solid (5.6 g, 69%). 
 
HPLC: tR = 5.1 min (100% purity, ELSD). 
ESI
+
/MS: m/z (%) 273.1 [Mmt]+ (100), 720.3 [M+H]+ (53). 
1
H NMR (500 MHz, CDCl3) two rotamers: δ = 13.55 and 13.40 (1H, br s, NH-Dde), 
7.25 – 6.94 (13H, m, 12 x CH-Mmt and CH-Cyt), 6.76 and 6.74 (2H, s, CH-Mmt), 
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4.97 and 4.96 (1H, s, CH-Cyt), 4.51 and 4.34 (2H, s, CH2COO), 4.33 and 4.03 (2H, 
s, CH2CO), 3.73 – 3.64 (7H, m, CH3O-Mmt and 2 x CH2N), 3.53 (3H, s, OCH3) 2.53 
and 2.48 (3H, s, CH3C), 2.26 and 2.25 (4H, s, CH2-Dde), 0.93 and 0.92 (6H, s, 
(CH3)2-Dde). 
13
C NMR (125 MHz, CDCl3) two rotamers: δ = 199.1 and 196.7 (CO), 174.1 and 
173.8 (C), 169.8 and 169.3 (CO), 168.6 and 167.8 (CO), 165.9 (C), 158.7 (C), 155.8 
(CO), 146.2 and 145.9 (CH), 144.1 (C), 135.8 (C), 129.9 (CH), 128.6 (CH), 128.3 
(CH), 127.5 (CH), 113.6 (CH), 108.3 and 108.2 (C), 94.7 and 94.6 (CH), 70.6 (C), 
60.3 (CH2), 55.2 (CH3), 52.8 and 52.5 (CH3), 51.9 CH2), 49.0 and 48.7 (CH2), 48.5 





















 Compound 2.17 A was synthesised from 2.16 (5.5 g, 11.8 mmol) in analogy 
to 2.17 T and obtained as a white solid (4.7 g, 53%). 
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HPLC: tR = 5.7 min (100% purity, ELSD). 
ESI
+
/MS: m/z (%) 273.0 [Mmt]+ (100), 744.3 [M+H]+ (29). 
1
H NMR (250 MHz, d6-DMSO) two rotamers: δ = 13.27 and 13.16 (1H, br s, NH-
Dde), 8.09 and 8.08 (1H, s, CH-pur), 7.88 (1H, s, CH-pur), 7.33-7.20 (12H, m, CH-
Mmt), 6.85 (2H, d, J = 8.8 Hz, CH-Mmt), 5.25 and 5.08 (2H, s, CH2COO), 4.53 and 
4.12 (2H, s, CH2CO), 3.78 (2H, br s, CH2N), 3.74 and 3.60 (3H, s,OCH3), 3.72 (3H, 
s, CH3O-Mmt), 3.53 (2H, m, CH2N), 2.56 and 2.46 (3H, s, CH3C), 2.30 and 2.26 
(4H, s, CH2-Dde), 0.94 and 0.93 (6H, s, (CH3)2-Dde). 
13
C NMR (62.5 MHz, d6-DMSO) two rotamers: δ = 196.5 and 196.4 (CO), 
173.2(CO), 169.8 (CO), 169.4 (CO), 167.0 (C), 157.7 (C), 153.4 (C), 151.2(C), 145.2 
(C), 142.3 and 142.2 (C), 137.1 (C), 129.8 (CH), 128.4 (CH), 127.6 (CH), 126.5 
(CH), 119.8 (C), 113.0 (CH), 107.4 and 107.3 (C), 70.0 (C), 54.9 (CH3), 52.4 (CH2), 












cyclohexyliden)-ethylamino]-ethyl}-glycinate (2.17 T) (2.3 g, 5 mmol) was 
suspended in 1:1 (v/v) mixture of MeOH and 2 M Cs2CO3 (50 mL) and stirred for 1 
h. After evaporation of MeOH in vacuo, the aqueous phase was acidified with 4 M 
HCl to pH 1 and the solvents were removed in vacuo. The residue was treated with 
hot 2-propanol (50 mL) and the hot suspension was passed through a filter. The 
filtrate was collected and 2-propanol was removed in vacuo. The residue was 
sonicated in water (25 mL), the resulting suspension was collected by filtration, 
giving PNA-T as an off-white solid (1.63 g, 73%). 
 
HPLC: tR = 3.3 min (100% purity, ELSD). 
ESI
-
/MS: m/z (%) 895.3 [2M-H]- (100). 
1
H NMR (250 MHz, d6-DMSO) two rotamers: 13.18 and 13.11 (1H, br s, NH-Dde), 
11.25 (1H, br s, NH), 7.30 and 7.28 (1H, d, J = 1.1 Hz, CH), 4.65 and 4.49 (2H, s, 
CH2COO), 4.38 and 4.09 (2H, s, CH2CO), 3.70 and 3.60 (3H, s, OCH3), 3.67 (2H, br 
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s, CH2N), 3.50 (2H, br s, CH2N), 2.51 and 2.45 (3H, s, CH3C-Dde), 2.28 and 2.25 
(4H, s, CH2-Dde), 1.73 (3H, s, CH3), 0.93 and 0.92 (6H, s, (CH3)2-Dde). 
13
C NMR (125 MHz, CDCl3) two rotamers: δ = 196.9 and 196.7 (CO), 173.5 (CO), 
171.1 and 170.7 (CO), 168.4 and 167.7 (CO), 164.7 (C), 151.4 and 151.3 (CO), 
142.4 and 142.3 (CH), 108.5 (C), 107.8 and 107.6 (C), 52.8 (CH2), 49.2 (CH2), 48.1 




















 PNA-C was synthesised from 2.17 C (500 mg, 0.7 mmol) in analogy to 
PNA-T and obtained as a yellowish solid (395 mg, 80%). 
 
HPLC: tR = 5.1 min (100% purity, ELSD). 
ESI
-
/MS: m/z (%) 704.2 [M-H]- (100). 
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1
H NMR (500 MHz, CD3OD) two rotamers: δ = 7.34-7.24 (11H, m, 10 x CHMmt 
and CH-Cyt), 7.19 (2H, d, J = 8.8 Hz, CH-Mmt), 6.89 (2H, d, J = 8.8 Hz, CHMmt), 
5.19 and 5.17 (1H, d, J = 7.5 Hz, CH-Cyt), 4.70 and 4.57 (2H, s, CH2COO), 4.29 and 
4.12 (2H, s, CH2CO), 3.79 (3H, s, CH3O-Mmt), 3.78-3.64 (4H, m, 2 x CH2N), 2.58 
and 2.55 (3H, s, CH3C), 2.33 and 2.29 (4H, s, 2 x CH2-Dde), 0.98 and 0.95 (6H, s, 
(CH3)2-Dde). 
13
C NMR (125 MHz, CD3OD) two rotamers: δ = 200.1 and 199.8 (CO), 176.0 (C), 
172.8 and 172.4(CO), 170.5 and 169.7 (CO), 167.5 and 167.4 (C), 160.5 (C), 148.5 
and 148.3 (CH), 145.5 (C), 137.0 (C), 131.7 and 131.4 (CH), 130.2 (CH), 130.0 
(CH), 129.5 (CH), 128.7 (CH), 128.6 (CH), 127.5 (CH), 114.7 and 113.8 (CH), 
109.2 and 109.1 (C), 96.7 and 96.6 (CH), 72.1(C), 55.8 and 55.7 (CH3), 53.5 (CH2), 
51.2 (CH2), 50.7 (CH2), 49.8 (CH2), 42.7 and 42.1 (CH2), 31.1 (C), 28.5 (CH3), 18.4 




















 PNA-A was synthesised from 2.17 A (500 mg, 0.7 mmol) in analogy to 
PNA-T and obtained as a white solid (416 mg, 85%). 
 
HPLC: tR = 5.5 min (92% purity, ELSD). 
ESI
-
/MS: m/z (%) 728.2 [M-H]- (100). 
1
H NMR (250 MHz, d6-DMSO) two rotamers: 13.25 and 13.15 (1H, br s, NHDde), 
8.11 and 8.08 (1H, s, CH-pur), 7.87 (1H, s, CH-pur), 7.33-7.18 (12H, m, CH-Mmt), 
6.85 (2H, d, J = 8.8 Hz, CH-Mmt), 5.24 and 5.07 (2H, s, CH2COO), 4.40 and 4.03 
(2H, s, CH2CO), 3.70 (2H, br s, CH2N), 3.72 (3H, s, CH3O-Mmt), 3.56 (2H, br s, 
CH2N), 2.56 and 2.46 (3H, s, CH3C), 2.29 and 2.26 (4H, s, CH2-Dde), 0.93 and 0.92 
(6H, s, (CH3)2-Dde). 
13
C NMR (125 MHz, CDCl3) two rotamers: δ = 196.5 (CO), 173.1 (CO), 
170.7(CO), 170.2 (CO), 167.6 and 166.8 (C), 157.6 (C), 153.3 (C), 151.1 (CH), 
149.0 (C), 145.1 (C), 142.1 (CH), 137.0 (C), 129.8 (CH), 128.4 (CH), 127.6 (CH), 
126.5 (CH), 119.7 (C), 112.9 and 112.7 (CH), 107.3 and 107.2 (C), 69.8 (C), 54.9 
(CH3), 52.3 (CH2), 49.1 (CH2), 47.9 and 46.6 (CH2), 43.7 (CH2), 40.9 (CH2), 29.7 















 To a stirred suspension of Fmoc-Lys-OH (2.18) (5 g, 13.6 mmol) in ethanol 
(100 mL) was added Dde-OH (2.3) (5 g, 27.2 mmol) and TFA (104 µL, 1.36 mmol). 
The mixture was refluxed for 60 h and concentrated in vacuo. The orange residue 
was dissolved in EtOAc (200 mL), washed with 1 M aqueous KHSO4 (2 x 100 mL), 
brine (1 x 100 mL), dried over MgSO4 and the solvent was evaporated in vacuo. The 
resulting yellow oil was triturated with hexane to give a yellowish solid that was 
recrystallised from ethyl acetate/hexane to afford Fmoc-Lys(Dde)-OH (2.19) as an 
off-white solid (5 g, 69%). 
HPLC: tR = 5.1 min (90% purity, ELSD). 
ESI
+
/MS: m/z (%) 533.2 [M+H]+ (100). 
1
H NMR (250 MHz, d6-DMSO): δ = 13.34 (1H, br s, COOH), 12.72 (1H, br s, 
NHDde), 7.97 (2H, d, J = 7.4 Hz, CH-Fmoc), 7.81 (2H, d, J = 7.2 Hz, CH-Fmoc), 
7.50 (2H, t, J = 7.4 Hz, CH-Fmoc), 7.42 (2H, d, J = 7.2 Hz, CH-Fmoc), 5.84 (1H, br 
s, NH), 4.41-4.38 (1H, m, CH), 4.33 (2H, d, J = 8.2 Hz, CH2-Fmoc), 4.09-3.95 (1H, 
m, CH-Fmoc), 3.57-3.49 (2H, m, CH2-NH), 2.55 (3H, s, CH3-Dde), 2.32 (4H, s, 
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CH2-Dde), 1.91-1.72 (2H, m, CH2-Lys), 1.71-1.56 (2H, m, CH2-Lys), 1.55-1.37 (2H, 
m, CH2-Lys), 1.00 (6H, s, (CH3)2-Dde). 
13
C NMR (62.5 MHz, d6-DMSO): δ = 196.3 (CO), 173.8 (CO), 172.7 (C=CNH), 
156.1 (COO), 143.7 (C), 140.6 (C), 127.5 (CH), 127.0 (CH), 125.2 (CH), 120.0 
(CH), 106.8 (C), 65.5 (CH2), 53.6 (CH), 52.2 (2 x CH2), 46.6 (CH), 42.4 (CH2NH), 
30.3 (CH2), 29.6 (CH2), 28.0 (C(CH3)2), 27.8 (C(CH3)2), 23.0 (CH2), 17.3 (CH3). 
 
6.2.2 Synthesis PNA-enocoded FRET based D-amino acid containing 
peptide library (L 2.1). 
 
 
 Deprotection, coupling (method 1) and cleavage protocols are described in 
section 6.1.2. Fmoc-Rink-amide linker (53 mg, 100 µmol, 5 eq) was first attached to 
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PEGA resin (337 mg, 20 µmol) followed by Fmoc deprotection and stepwise 
couplings with Fmoc-Lys(Dde)-OH 2.19 (53 mg, 100 µmol, 5 eq), Fmoc-Ahx-OH 
(35 mg, 100 µmol, 5 eq), and Fmoc-Lys(Alloc)-OH 2.21 (45 mg, 100 µmol, 5 eq). 
The synthesis was then carried out as follows: [1] split resin 2.24 into 5 pools (4 
µmol resin loading each pool) [2] Fmoc deprotection; [3] Fmoc-amino acid 
couplings (20 µmol per pool, 5 eq; method 1, section 6.1.2.4); [4] Dde deprotection; 
[5] Dde/Mmt-protected PNA monomer couplings (20 µmol per pool, 5 eq; method 1, 
section 6.1.2.4); repeat [4] and [5] twice (amino acids and Dde/Mmt-protected PNA 
monomers used in steps [3] and [5] were according to Table 2.3); [6] the five resin 
pools were then mixed, repeat steps from [1] to [6] twice. Steps [1] to [5] were 
repeated using “TCC” as PNA code (N to C), giving raise to 2.26 (in 5 pools). For 
each pool, Fmoc-Ahx-OH (7.0 mg, 20 µmol, 5 eq) and 5(6)-carboxyrhodamine B 
(18.6 mg, 20 µmol, 5 eq) were respectively coupled followed by Alloc-deprotection 
and coupling with 5(6)-carboxyfluorescein (7.5 mg, 20 µmol, 5 eq). Before resin 
cleavage, the sub-library was treated with 20% piperidine in DMF (6 mL, 2 cycles of 
10 min)(97), washed with DMF (2 x 5 mL) and DCM (2 x 5 mL). Final cleavage from 
the resin was carried out using TFA/TIS/DCM (90/5/5) (1 mL) for 1 h to afford the 
sub-library of L 2.1 as a magenta solid after precipitation with cold Et2O. 
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RHOD = Rhodamine B amide















 Deprotection, coupling (method 2) and cleavage protocols are described in 
section 6.1.2. Fmoc-Rink-amide linker (77 mg, 142 µmol, 4 eq) was first attached to 
the PEGA resin (600 mg, 36 µmol) followed by Fmoc deprotection and stepwise 
couplings with Fmoc-D-Lys(Dde)-OH (2.31). The synthesis was then carried out as 
follows: [1] split resin 2.32 into 6 pools (6 µmol resin loading each pool); [2] Fmoc 
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deprotection; [3] Fmoc-amino acid couplings (24 µmol per pool, 4 eq; method 2, 
section 6.1.2.4); [4] Dde deprotection; [5] Dde/Mmt-protected PNA monomer 
couplings (24 µmol per pool, 4 eq; method 2, section 6.1.2.4); repeat [4] and [5] three 
times (amino acids and Dde/Mmt-protected PNA monomers used in steps [3] and [5] 
were according to Table 2.4); [6] the five resin pools were then mixed, repeating 
steps from [1] to [6] three times, giving raise to resin 2.34. To one fourth of resin 
2.34 (9 µmol), Fmoc-Ahx-OH (12.7 mg, 36 µmol, 4 eq) and 5(6)-carboxyfluorescein 
(13.5 mg, 36 µmol, 4 eq) were respectively coupled followed by Dde-deprotection 
and coupling with 5(6)-carboxyrhodamine B (17.5 mg, 36 µmol, 4 eq). The library 
was cleaved using the same condition as for L 2.1. 
























 Resin 2.33 (18 µmol) was coupled (method 2) to 5-hexynoic acid (7.9 µL, 72 
µmol, 4 eq) followed by Fmoc-deprotection. After Dde-deprotection, Fmoc-Ahx-OH 
(25.4 mg, 72 µmol, 4 eq) and 5(6)-carboxyrhodamine B (35.2 mg, 72 µmol, 4 eq) 
were respectively coupled. The library was cleaved using the same conditions as for 
L 2.1 (see section 6.1.2.6). 
6.2.5 Synthesis of a 625 member PNA-encoded peptide library of potential 




























 Deprotection, coupling (method 2) and cleavage protocols are described in 
section 6.1.2. Fmoc-Rink-amide linker (53 mg, 100 µmol, 5 eq) was first attached to 
PEGA resin (337 mg, 20 µmol) followed by Fmoc deprotection and coupling with 
Fmoc-Lys(Dde)-OH 2.19 (53 mg, 100 µmol, 5 eq) and Fmoc-Ahx-OH (35 mg, 100 
µmol, 5 eq). The synthesis was then carried out as follows: [1] split resin 2.23 into 5 
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pools (4 µmol resin loading each pool); [2] Fmoc deprotection; [3] Fmoc-amino acid 
couplings (20 µmol per pool, 5 eq; method 2, section 6.1.2.4); [4] Dde deprotection; 
[5] Dde/Mmt-protected PNA monomer couplings (20 µmol per pool, 5 eq; method 2, 
section 6.1.2.4); repeat [4] and [5] twice (amino acids and Dde/Mmt-protected PNA 
monomers used in steps [3] and [5] (see Table 2.5); [6] the five resin pools were then 
mixed, repeating steps from [1] to [6] twice. Steps [1] to [5] were repeated and the 
resin was left in 5 portions. Each portion was treated with 1:1 Ac2O:Py (2 mL) for 
1.5 h following Fmoc deprotection. After the Dde deprotection, Fmoc-Ahx-OH (7.0 
mg, 20 µmol, 5 eq) and 5(6)-carboxyfluorescein (7.5 mg, 20 µmol, 5 eq) were 
respectively coupled. Before cleavage, the sub-library was treated with 20% 
piperidine in DMF (6 mL, 2 cycles of 10 min)(100), washed with DMF (2 x 5 mL) and 
DCM (2 x 5 mL). Final cleavage from the resin was carried out using TFA/TIS/DCM 
(90/5/5) (1 mL) for 1 h to afford the sub-library of L 2.4 as a yellowish solid after 
precipitation with cold Et2O. 
6.3 Experimental to Chapter 3. 
6.3.1 Screening of library L 2.1 as potential substrate for chymopapain. 
PBS buffer: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4. 
Enzyme Buffer: 50 mM sodium acetate, 2 mM cysteine, 0.1 mM EDTA, pH 6.2. 
 
A solution of library L 2.1 (16 µL, 3.4 nmol) in DMSO was diluted into 59 µL of 
PBS buffer and heated at 90°C for 20 min. The solution was cooled to room 
temperature, 20 µL of 3 µM chymopapain was added and the mixture was incubated 
at 37°C for 18 h. One volume of this solution was diluted with one volume of 
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GenHyb buffer (Genetix) and denatured by heating at 90°C for 20 min. 100 µL of the 
solution was added onto a DNA microarray (see 3.4.1) at 60°C. The temperature was 
then lowered to 25°C over a period of 20 h. After hybridisation, the chips were 
washed with 4x SSC (20 mL); washed twice with 2x SSC, 0.1% SDS (20 mL) at 
25°C for 5 min; 0.2x SSC for 1 min; 0.1x SSC for 1 min and spin-dried by 
centrifugation (1000 rpm for 10 min). 
6.3.2 Screening of library L 2.2 as a potential substrate for chymopapain. 
 Library L 2.2 was screened as described in 6.3.1 except that the reaction 
mixture was hybridised onto a 22,500 customised DNA chip from Oxford Gene 
Technology (Oxford, UK) and after the hybridisation, the chips were washed twice 
(20 mL) for 10 min at 30°C with the following buffer (100 mM NaCl, 10 mM citric 
acid, 0.7% (w/v) N-lauroylsarcosine sodium salt, 0.1 mM EGTA, pH 7.5), rinsed 
with distilled water (20 mL) and spin-dried by centrifugation (1000 rpm for 10 min). 
6.3.3 Screening of library L 2.2 as a potential substrate for Gumby. 
Enzyme Buffer: 20 mM HEPES, 100mM NaCl, 2 mM DTT, pH 7.5 
 
Library L 2.2 (60 µL, 600 pmol) in PBS buffer was screened against Gumby (2 µL, 
11.4 pmol) as described in 6.3.1 except that the reaction mixture was hybridised onto 
a 22,500 customised DNA chip from Oxford Gene Technology (Oxford, UK). After 
the hybridisation, the chips were washed as described in 6.3.2. 
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6.4 Experimental to Chapter 4. 
6.4.1 Screening of library L 2.3 as potential substrates for a self 
promoting Huisgen 1,3-dipolar cycloaddition. 
 An aqueous mixture (25 µL) of L 2.3 (20 µM) and compound 4.2 (20 µM) 
was incubated at 37°C for 18 h. Excess 4.2 was removed by a centrifugal filter 
device (Millipore) and the reaction mixture was concentrated by freeze drying. The 
concentrated library was solubilised in 50 µL of water and diluted with 50 µL of 2x 
GexHyb buffer (Genetix) and hybridised onto a 22,500 customised DNA microarray 
as described in 6.3.2. 
6.5 Experimental to Chapter 5. 
6.5.1 Screening of library L 2.4 for the discovery of cell-penetrating 
peptides. 
The screening of library L 2.4 was performed by Nina Svensen as a part of her PhD 
thesis(101). 
6.5.2 Cellular delivery of “hit” from CPP library. 
Cells were suspended to the appropriate cell density in fresh growth media - Roswell 
Park’s Memorial Institute (RPMI, sigma aldrich) for HeLa cells and Dulbecco’s 
Modified Eagle Medium (DMEM, sigma aldrich) for B16F10 cells - before seeding 
onto polystyrene well-plates (Nunc). Cells were incubated (37 ºC/5% CO2) for 24 
hours to allow adhesion. The peptides were added into the growing media to obtain 
the desired final concentration. Cells were incubated in the presence of peptide 5.2 
and peptide 5.3 (37 ºC/5% CO2). 
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6.5.3 Flow cytometry analysis. 
 In preparation for flow cytometric analysis, the old media was removed from 
cell cultures and the cells were washed with PBS and detached by trypsination at 
37ºC. Detached cells were collected in 2% FBS/PBS with or without 0.2% trypan 
blue. Samples were analysed by flow cytometry using a BD Biosciences FACSDiva 
and associated software. Untreated cells were defined as having 0% uptake. 
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